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The Role of Neuroinflammation in Alzheimer’s Disease 
Dimitrios Ion Sideris 
Neuroinflammation is believed to play a key role in Alzheimer’s disease, as evidenced 
by recent genome wide association studies highlighting several risk genes associated 
with the immune response. Misfolded and aggregated proteins bind to pattern 
recognising receptors on glial cells in the brain, causing the production and release of 
pro-inflammatory messengers, which contribute to disease progression. By studying 
the relationship between protein aggregation and neuroinflammation at early stages, 
we can begin to uncover the mechanisms underlying the initiation of the disease. 
Chapter 3 describes the optimisation of a neuroinflammation assay that uses a BV2 
microglial cell line to test the inflammatory potential of synthetic amyloid beta 42 
aggregates. In conjunction with a liposome-permeability assay and an 
immunoprecipitation assay, this assay has been used to validate a proprietary amyloid 
beta 42 antibody from MedImmune (now AstraZeneca).  
Most neuroinflammation studies have focused extensively on synthetic aggregates 
and to a much lesser extent on endogenous soluble aggregates from human tissue. 
The aggregates present in humans are still poorly characterised due to a lack of 
suitable methods required for characterising the low concentration of heterogeneous 
aggregates present.  
In Chapter 4, a variety of biophysical methods have been employed to characterise 
the soluble aggregates present in human Alzheimer’s disease brains at Braak stage 
III. We have identified the similarities and differences between the soluble aggregates 
in eight different regions by providing a detailed characterisation of their size, 
morphology, structure, neurotoxicity, inflammatory potential, and capability to 
permeabilise a lipid membrane. This data shows that soluble aggregates of a range of 
sizes and morphologies, capable of causing inflammation, are already present in all 
brain regions at Braak stage III and that aggregation is occurring by the same 
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1: Literature Review 
Parts of this chapter have been adapted from the following published manuscript: 
Dimitrios I. Sideris, John S. H. Danial, Derya Emin et al. Soluble amyloid beta-containing aggregates 
are present throughout the brain at early stages of Alzheimer’s disease, Brain Communications, 2021. 
1.1. Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that targets the 
central nervous system. It is the leading cause of dementia, accounting for 60-80 
percent of reported cases.1 Dementia is characterised by a wide range of symptoms 
including memory loss, problems with language, difficulties with problem-solving, 
executive dysfunction and general cognitive impairment. These symptoms are a 
product of the degeneration of neuronal cells, as well as the dysfunction of synaptic 
connections between them. In patients with advanced AD, the loss of neurons leads 
to a significant physical shrinkage of the brain, notably with a great reduction in grey 
matter and the formation of large empty vacuoles within the brain tissue.2,3 AD is most 
prevalent in people over the age of 65 and is not part of the normal ageing process. 
The progressively debilitating nature of this disease makes daily tasks impossible to 
carry out without the help of a carer. In the UK, the cost of dementia research and 
social care has reached £26.3 billion a year and is on the rise. When measured in 
2014, approximately 850,000 people were suffering from dementia in the UK alone. 
This number is increasing dramatically and is estimated to reach two million by 2050.4 
Dementia and AD are currently the leading cause of death in the UK.5 Due to an ageing 
population, there is a socio-economic urgency to find a prevention or therapeutic 
strategy for AD. 
In order for a therapy or preventative treatment to be developed, there needs to be a 
better understanding of AD’s complex aetiology. AD can be split into two subtypes, 
familial and sporadic. Familial AD is the rarer form, accounting for 1% of cases and is 
caused by a subset of dominantly inherited genes that can be passed from one 
generation to the next. These include the genes that encode presenelin-1 (PS-1), 
presenelin-2 (PS-2) and the amyloid precursor protein (APP), all of which affect the 
processing of the amyloid beta (Aβ) protein, which is heavily implicated in AD. 6–8  
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Sporadic AD develops through environmental risk factors such as age, as well as non-
dominant genetic mutations, which generally affect the way Aβ is cleared. 
Apolipoprotein E (ApoE) is the strongest sporadic risk gene for AD. There are three 
types of APOE in humans, APOEε2, APOEε3, APOEε4. APOE is secreted by 
astrocytes and lipidated by ABCA1. Lipidated APOE has been shown to interact with 
Aβ aggregates and triggering receptor expressed on myeloid cells 2 (TREM2), another 
genetic risk factor for AD, and binds to low-density lipid (LDL) receptors, such as LRP1, 
LDLR, VLDLR, ApoER2.9 Aβ42 coupled with APOEε3 and APOEε4 is more toxic than 
when coupled with APOEε2,10 further highlighting their involvement in AD pathology. 
GWAS studies have identified over 25 genetic loci that cause genetic risks for sporadic 
AD, several which are highly expressed in microglia.11–13 These risk factors can 
contribute to the assembly of toxic proteins that are believed to cause downstream 
toxic events, leading to disease pathology. The essential diagnostic hallmarks of AD 
include extracellular Aβ plaques and intracellular neurofibrillary tangles consisting of 
hyperphosphorylated tau protein.14,15 During disease progression, neurofibrillary 
tangle pathology tends to develop and spread throughout the brain in distinct stages 
(Braak stages) that correlate with the degree of Aβ pathology (Thal phases) as well as 
cognitive decline (Figure 1).16,17 Tau inclusions first start appearing in the entorhinal 
cortex and neighbouring areas (stages I/II), followed by the hippocampus and frontal 
cortex (stages III/IV), which then spread to most of the neocortex. Aβ pathology tends 
to originate in the frontal cortex (phase 1), and spreads through the neocortex, 
hippocampus, amygdala, basal ganglia (phases 2/3), before reaching the midbrain, 
lower brainstem, and cerebellum (phases 4/5) in advanced AD.18 The brain regions 
that are affected early are associated with memory (hippocampus/entorhinal cortex), 
higher cognitive function, emotions, impulse control and problem solving (frontal lobe). 
 
 




Figure 1: Aβ and tau pathology in Alzheimer's disease 
During AD progression, Aβ (blue) and tau (green) pathology develop through the brain in several distinct 
stages that correlate with cognitive decline. Adapted from [18,19].  
AD genetics affect Aβ processing (familial genes) and Aβ clearance (sporadic genes), 
suggesting that Aβ pathology might precede tau pathology. However, Aβ-induced 
neuronal death has been shown to be tau-dependent both in vivo and in cultured 
neurons, suggesting that while Aβ might be upstream of tau, tau is responsible for the 
neuronal death in AD.20 Toxicity from Aβ and tau pathology can occur independently, 
however Aβ buildup has been shown to induce tau hyperphosphorylation, suggesting 
a link between the two.21 Further highlighting this link, tau has been shown to be able 
to influence Aβ aggregation, as seen from the decreased amyloidogenic processing 
of APP in tau knockout APP/PS1 mice.22 A better understanding is required of how 
these proteins assemble and their mechanisms of toxicity. 
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1.2. Amyloid Assembly 
The aggregation of monomeric proteins into toxic species is a common mechanism 
involved in many neurodegenerative diseases23. The protein most strongly associated 
with AD pathology is the 42-amino acid protein, Aβ. The Aβ peptide is formed by the 
sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases 
(Figure 2). The cleavage of APP can occur on the plasma membrane, the 
endoplasmic reticulum, golgi apparatus, or in endocytic vesicles.24,25 APP’s functional 
role remains elusive, but has recently been suggested to be a modulator of synaptic 
transmission.26 
 
Figure 2: Amyloidogenic vs non-amyloidogenic pathways of APP cleavage 
APP = amyloid precursor protein, sAPPα = soluble peptide APP-α, sAPPβ = soluble peptide APP-β, 
AICD = APP intracellular domain, α-CTF = α-C terminal fragment, β-CTF = β-C terminal fragment  
The non-amyloidogenic pathway (left) involves the proteolytic cleavage of APP by α- and γ-secretase, 
forming sAPPα and C-terminal fragments (α-CTF, AICD and p3). The amyloidogenic pathway (right) 
involves APP cleavage by β- and γ-secretase, resulting in the formation of sAPPβ, C-terminal fragments 
(β-CTF and AICD) and Aβ. Two long forms of Aβ, 48 and 49 amino acids long, are produced and 
sequentially cleaved causing tripeptide or tetrapeptide release giving rise to a range of different Aβ 
peptide lengths (37-46 amino acids).27,28 The Aβ42 form is the most susceptible to aggregation, which 
results in cytotoxic effects.29  
The Aβ42 peptide is non-toxic in its monomeric form but is highly prone to misfolding 
and aggregating into toxic protein species. As aggregation progresses, the amyloid 
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degrade. The amyloid assembly mechanism follows a lag, elongation and plateau 
phase (Figure 3).30 
 
Figure 3: Kinetics of amyloid formation 
ThT = Thioflavin T 
Amyloid fibrils are formed from the misfolding and aggregation of monomeric amyloid peptides into 
soluble prefibrillar aggregates, in what is known as the lag or nucleation phase. By acting as a template 
for other intermediates, these early aggregates promote rapid fibril growth until a maximum steady state 
is reached (plateau phase).31 Amyloid aggregation kinetics can be measured by ThT fluorescence, a 
dye that fluoresces when bound to beta-sheet structures. 
Within these three macroscopic phases, there are four smaller events taking place. 
Primary nucleation, elongation, secondary nucleation and fragmentation occur in all 
three kinetic stages, although at varying rates.32 These are dependent on rate 
constants, as well as the concentrations of reacting protein species. Following the 
formation of soluble early aggregates (nuclei), monomeric proteins begin assembling 
at the ends of existing aggregates and form insoluble fibrillar structures. Fibrils can act 
as a platform from which other proteins can then begin to assemble; a process known 
as secondary nucleation.33 In some cases, fibrils are also prone to fragmentation, 
which reduces them to shorter assemblies. This enhances amyloid cytotoxicity, as 
shorter fibrils tend to cause more membrane disruption than longer fibrils.34 Aβ is also 
prone to being post-translationally modified. Nitrated, pyroglutamylated or 
phosphorylated Aβ can cause an increase in reactive oxygen species (ROS), which 
leads to neurotoxicity.35 
Fibrils 






















Chapter 1: Literature Review 
6 
 
The amyloid assembly mechanism has become an important target for drug therapies, 
however, there needs to be a better understanding of which stage of the assembly to 
focus on. Some literature suggests that early prefibrillar soluble aggregates, termed 
oligomers, are the most toxic to cells.36–38 However, the heterogeneous nature of Aβ42 
aggregation has left this question up for debate. This is further complicated by the fact 
that synthetic or recombinant Aβ42 is extensively used for experimentation. While they 
can be used to provide a rough idea of amyloid aggregation kinetics and cytotoxicity, 
it is unclear how physiologically relevant these proteins are to the endogenous Aβ42 
found in human patients. This is because unlike in vitro aggregates, endogenous Aβ 
can undergo post-translational modifications, that can cause increased aggregation, 
neurotoxicity, amyloidogenicity, and suppression of hippocampal long-term 
potentiation (LTP).35 Furthermore, many studies tend to separate Aβ42 aggregates 
based on size, using size exclusion chromatography, ultrafiltration, or fractionation 
using a chemical gradient. However, size does not necessarily distinguish soluble 
aggregates from fibrils; it is the structure that seems to be of more importance.39 
The assembly of the Aβ42 peptide plays a critical role in the initiation of AD, as 
supported by the genetics of APP, PS1, and PS2. It has given rise to the amyloid-
cascade hypothesis; the idea that genetic and environmental risk factors lead to the 
production and aggregation of Aβ42, followed by downstream toxic events resulting in 
synaptic and neuronal dysfunction and loss.40–43 These toxic events include 
widespread oxidative stress, glutamate excitotoxicity, tau aggregation and 
neuroinflammation. 
1.3. Neuroinflammation 
The innate immune response in the brain is triggered by several different factors, 
including trauma, invading pathogens and the presence of toxic peptides.44 This 
response is crucial as it helps control the disturbance of the initial infliction event by 
repairing damaged tissue and removing dead cells. The immune response is mediated 
by glial cells, namely astrocytes and microglia.45 They help provide metabolic and 
structural support to neurons and protect the brain from pathogens. At the early stages 
of AD, astrocytes and microglia gather around senile plaques to clear Aβ deposits 
through phagocytosis.46 However, in response to chronic inflammatory signals such 
as damage-associated molecular patterns (DAMPs), which include Aβ aggregates, 
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senile plaques and tau neurofibrillary tangles, glial cells are unable to carry out their 
function and adopt an altered proinflammatory morphology.47 In this state, the 
neuroprotective actions of these cells are outweighed by the production of 
proinflammatory cytokines and chemokines. An overproduction of these cytokines can 
cause significant damage, by inducing Aβ42 aggregation, tau hyper-phosphorylation, 
blood-brain barrier (BBB) permeability and inhibiting neurogenesis, resulting in 
neurodegeneration (Figure 4).48–50 It is widely reported that Aβ42 aggregates can 
cause neuroinflammation, which in turn induces Aβ42 aggregation, suggesting the two 
mechanisms might be in a positive feedback loop.51 Cytokine release from microglia 
promotes the astrocytic proinflammatory state, and vice versa.  This active glial 
phenotype has been shown to play a role in early disease.52 As the disease 
progresses, there is an increase in active microglia, with a change towards dystrophic 
microglia in the late stages of the disease.53  
 
Figure 4: The role of neuroinflammation in Alzheimer’s disease 
TNFα = tumour necrosis factor α, IL = interleukin, iNOS = inducible nitric oxide synthase 
In response to the presence of chronic inflammatory stimuli such as amyloid beta aggregates, microglia 
and astrocytes become activated. This triggers the release of proinflammatory cytokines, chemokines, 
and reactive oxygen species, an overproduction of which can result in neurodegeneration.  
In transgenic mouse models of AD, microglial activation in early disease can help with 
the clearance of Aβ deposits.54 It is possible that microglial activation is beneficial in 
early disease but becomes detrimental in later stages. Microglial activation relies on 
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the identification of inflammatory stimuli through various membrane pattern-
recognising receptors (PRR). 
AD patients have elevated levels of proinflammatory cytokines and chemokines such 
as TNFα, IL-1β, and IL-6 in their brain and CSF.55,56 Further evidence of the role of 
neuroinflammation in AD comes from GWAS studies that have identified several 
genetic risk factors such as TREM2, CLU, CR1 and CD33, all of which are involved in 
the innate immune system.57 Furthermore, the dysregulation of the complement 
protein system in AD, an integral component of the innate immune system, is believed 
to contribute to the neurotoxic effects of microglia and astrocytes,58 as well as cause 
direct damage through its cytotoxic effector, the membrane attack complex.59  
Aβ aggregates interact with cells through several mechanisms, including non-specific 
biophysical interactions with cell membranes resulting in a loss of normal barrier 
function, and specific receptor-mediated interactions on the cell membrane.60–63 The 
heterogeneity of Aβ aggregates makes them a diverse ligand for a wide range of 
possible receptors.64,65 Over 20 candidates have been proposed, including cellular 
prion protein,66 nicotinic acetylcholine receptors,67 glutamate receptors such as AMPA, 
NMDA and mGluR5,68–70 TREM2,71 ApoE,72 and toll-like receptors 2 and 4.73–75 These 
varied Aβ-receptor interactions are likely to be contributing to synaptic dysfunction and 
neurodegeneration.65 The toll-like receptor interactions are of particular interest due to 
their critical role in neuroinflammation. 
1.4. Toll-like Receptors 
The Toll-like receptor family plays a central role in the innate immune response by 
recognising pathogen-associated molecular patterns (PAMPs) and DAMPs. In the 
brain, these receptors are mostly found in glial cells, namely microglia and 
astrocytes,76 but have also been reported in less abundance in neurons.77 TLR4, a 
member of this receptor family, has been strongly implicated with AD pathology.74 Like 
other toll-like receptors, TLR4 is activated via ligand-induced dimerisation, mediated 
by membrane-anchored co-receptor proteins (e.g. CD14) and cytoplasmic 
Toll/Interleukin-1 receptor (TIR) domain-containing adaptor proteins (e.g. Mal, 
MyD88). This leads to a downstream signalling cascade, causing the translocation of 
transcription factors into the nucleus, resulting in proinflammatory cytokine and 
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chemokine production (Figure 5). One of these cytokines, tumour necrosis factor α 
(TNFα), plays a central role in neuroinflammation and AD pathology.  
 
Figure 5: TLR4 MyD88-dependent signalling (simplified) 
LPS = lipopolysaccharide, TLR4 = toll like receptor 4, CD14 = cluster of differentiation 14, MyD88 = 
myeloid differentiation primary response 88, IRAK = interleukin-1 receptor-associated kinase, TRAF6 = 
TNF receptor-associated factor 6, TAK1 = transforming growth factor β-activated kinase 1, JNK = c-Jun 
N-terminal kinase, IKK = inhibitor of nuclear factor-kΒ kinase, AP-1 = activator protein 1, NF-κB = 
nuclear factor kappa-light-chain-enhancer of activated B cells.  
The recognition and binding of LPS or other PAMPs causes the dimerisation of the TLR4 receptor. 
Mediated by the CD14 co-receptor, the MyD88-dependent pathway recruits several proteins involving 
IRAKs, TRAFs, IKKs, JNK and p38, which cause the translocation of transcription factors NF-κB and 
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1.5. Tumour Necrosis Factor (TNF)α 
TNFα is an inflammatory cytokine secreted by activated macrophages/monocytes in 
response to inflammatory stimuli such as PAMPs. Most TNFα production occurs from 
the TLR4 MyD88-dependent downstream signalling cascade involving nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) translocation to the nucleus 
(Figure 5).78 TNFα can also be produced by the TLR4 MyD88-independent late 
activation of NF-κΒ, from other members of the TLR family, and from TNFR1 and 
TNFR2 signalling. Newly synthesised TNFα is trafficked from the Golgi apparatus to 
the cell membrane where it is cleaved by the TNFa-converting enzyme (TACE) 
ADAM17, a member of the ADAM family of disintegrin proteinases.75,79 Upon 
cleavage, this type 2 transmembrane protein (25.6 kDa) releases a soluble trimeric 
cytokine (17 kDa) that binds to several receptors, namely tumour necrosis factor 
receptor 1 (TNFR1) and TNFR2.80 TNFR1 contains a death-domain (DD) and typically 
carries out pro-apoptotic effects.81 TNFR2, which does not have a DD, is involved with 
promoting cell survival and proliferation, as well as pro-inflammatory cytokine 
production.82 This is done through the activation of cellular inhibitors of apoptosis 1 
and 2,83 NF-κB,84 and phosphatidylinositol 3-kinase-dependent signalling 
pathways.85,86   
Under physiological conditions, TNFα helps regulate the cells of the immune system, 
as well as support synaptic transmission and plasticity.87,88 However, in disease 
conditions TNFα forms a positive feed-back loop resulting in elevated levels of TNFα, 
which have been shown to enhance Aβ production,89,90 decrease microglial clearance 
of Aβ,91 increase neuronal cell death,92 and are associated with cognitive decline 
(Figure 6).82,93 These effects likely arise from a combination of mechanisms, including 
the direct binding of TNFα proteins to receptors on neurons (e.g. TNFR1 and 2), and 
the recruitment and activation of astrocytes, which in turn release a variety of toxins 
(e.g. transforming growth factor-β (TGFβ)) that have been implicated in AD 
pathology.94 
 




Figure 6: Toxic effects of TNFα 
Overproduction of TNFα can lead to several toxic effects, including the abnormal processing of the Aβ 
peptide, the loss of synaptic connections, neuronal dysfunction and loss, as well as neuronal cell death. 
These toxic effects can lead to dementia. 
Abnormal Aβ clearance may also be caused by TNFα, possibly through irregular 
cleavage of APP via the mitogen-activated protein kinase (MAPK) pathway90 and 
through NF-κB signalling.26 AD patients have significantly higher levels of TNFα in their 
blood96 and central nervous system97 than healthy adults, which correlates with 
disease progression.98 In post-mortem human AD brains, TNFα has been found 
localised around amyloid plaques.99 TNFR1 signalling is required for Aβ-induced 
neuronal death.100 Single-cell experiments have identified that paracrine signalling is 
important for regulating macrophage responses to TLR4 stimulation.101 It should be 
noted that as well as the production of TNFα, TLR4 activation can cause the priming 
of inflammasomes (e.g. nLRP3, nLRC4, AIM2); multimeric protein complexes that 
assemble in the cytosol, which can produce IL1β and IL-18 via caspase-1 activation.102 
IL1β is believed to play an important role in the initiation and propagation of 
neuroinflammation in AD, by providing a robust activation of astrocytes and 
microglia.103,104 IL1β is also thought to contribute to neuronal and synaptic dysfunction 
through several possible mechanisms, including the modulation of β-APP mRNA 
processing,105 and tau hyperphosphorylation.106,107  
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Along with playing an integral role in neuroinflammation, proinflammatory cytokines 
such as TNFα can cause high levels of excitotoxicity (Figure 7).108 Excitotoxicity 
occurs from the excessive stimulation of excitatory neurotransmitters such as 
glutamate, which can lead to the production of ROS, resulting in neuronal toxicity and 
cell death.  
 
Figure 7: The excitotoxic effects of TNFα 
TNFα is produced and released from microglia, which feeds back and stimulates further TNFα 
production. This promotes an extracellular release of glutamate from microglia and astrocytes, while 
inhibiting astrocytic glutamate uptake. In neurons, TNFα decreases the expression of inhibitory 
receptors, while activating excitatory receptors. This causes an influx of intracellular Ca2+, leading to 
the production of ROS. 
In the presence of interferon (IFN)-γ from T-cells, effector cells such as microglia 
secrete TNFα. This leads to glutamate release from gap junctions on the microglial 
membrane. TNFα also stimulates the microglial TNFR1, which produces even more 
TNFα, creating a positive feedback loop. This results in the stimulation of the TNFR1 
receptor on astrocytes, causing glutamate exocytosis, while inhibiting glutamate 
uptake. In neurons, excitatory receptors AMPA and NMDA are activated, while 
inhibitory GABAA receptors are supressed. This leads to a net increase of extracellular 
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calcium overload causes the production of ROS, resulting in the degeneration of 
neurons. Neuronal cell death further induces the microglial release of proinflammatory 
cytokines such as TNFα.108 
1.6. Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) 
Recent genome-wide association studies (GWAS) have identified TREM2, a gene 
involved in microglial inflammation, as a strong correlate with late onset AD 
pathology.109 Patients with a rare variant causing partial loss of TREM2, p.Arg47His 
(rs75932628), have a two-to-four time increase in risk of developing AD.110,111 Loss of 
function TREM2 variants affect the way microglial cells respond to inflammatory 
stressors, such as amyloid beta,112 resulting in impaired amyloid clearance. TREM2 
can bind to Aβ aggregates directly, which affects microglial responses.113 In TREM2 
variant AD, microglial cells stop undergoing apoptosis, and instead undergo 
senescence. Less microglia are also present around plaques and there are elevated 
levels of tau protein. In TREM2 variant AD, there is more insoluble tau than Aβ.53 
TREM2 plays a role in preventing tau seeding in neuritic plaques.114 TREM2 is cleaved 
by α-secretases ADAM10 and ADAM17, resulting in ectodomain shedding, which 
releases soluble TREM2 into the extracellular space. This is followed by further 
cleavage of the C-terminus by γ-secretase (Figure 8).115,116 Soluble TREM2 in CSF is 
a potential biomarker for disease progression from early AD to dementia, since it is 
elevated in AD patients and has significant changes with disease progression.117–119 
In addition, TREM2 has been shown to have reciprocal inhibition with TLR4, further 
supporting TREM2’s role in regulating neuroinflammation.120,121 
 
 




Figure 8: TREM2 cleavage 
TREM2 is cleaved by α-secretases ADAM 10 and/or ADAM 17, which releases soluble TREM2 into the 
extracellular space. This is followed by further intramembrane cleavage of CTF, which releases the 
intracellular domain (ICD) into the cytosol. Membrane TREM2 can recognise several ligands such as 
lipids, Aβ, ApoE and DNA, which cause signalling through DAP12 and regulate microglial activity. 
1.7. Therapies and Prevention Strategies 
AD is a multifaceted disease, with a vast array of potential therapeutic targets. This 
has made it very challenging for the pharmaceutical industry to develop an effective 
therapy or preventative treatment. Currently, only drugs that provide symptomatic 
relief are commercially available, including acetylcholinesterase inhibitors, such as 
donepezil, galantamine and rivastigmine, and NMDA receptor blockers such as 
memantine.122,123 However, as important as these drugs are for improving the quality 
of life of AD patients, they do not prevent or stop disease progression. 
In the past, pharmaceutical companies have tried a variety of disease-modifying 
therapies that aimed to slow the pathogenic process. In 1999, the first case of active 
immunotherapy against AD was published. This active vaccination was aimed at 
clearing Aβ from the brain of AD patients, by making the individuals generate their own 
antibodies to the amyloid beta antigen in the vaccine. However, 6% of the patients 
involved in the study developed severe meningoencephalitis,124 so other avenues 
were explored.  
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A crucial rate-limiting step for most neurodegeneration treatments has been the 
permeablisation of the BBB. The BBB is a network of proteins and endothelial cells 
that form a semi-permeable membrane that coats capillaries in the brain and prevents 
the passage of larger molecules into the brain tissue. The BBB is virtually impermeable 
to biologics due to their size (1-200 kDa), and only a small fraction (< 2%) of small 
molecule drugs (< 1 kDa) can pass through. Lipid-mediated free diffusion across the 
BBB requires lipid solubility and a molecular weight less than 400 Da.125,126 
Fortunately, pharmaceutical companies have been developing new ways of crossing 
the BBB. One promising method relies on fusing the drug with an endogenous peptide 
that undergoes receptor-mediated transport, most commonly using transferrin or 
insulin receptors.82,127 For larger drugs such as biologics, Roche has recently 
published the ‘Brain Shuttle’ for transporting antibodies through the BBB.128 
Small molecule drugs have been tested against a wide range of therapeutic targets. 
These drugs are less target-specific than biologics, but have better distribution, cell 
permeabilisation, and can be administered orally. One of the major targets for 
intervention using small molecule drugs has been γ-secretase, the enzyme involved 
in the amyloidogenic cleavage of APP. However, many challenges emerged from this 
target as γ-secretase is responsible for the cleavage of over 50 other proteins. 
Additionally, it is an important regulator of the proteolysis of Notch.129 Perturbing these 
physiological processes has led to severe adverse effects from γ-secretase inhibitors 
such as Semagacestat and Avagacestat.130,131 A more recent development focuses 
on the modulation of γ-secretase rather than inhibition, shifting the cleavage of APP 
towards the production of less toxic Aβ peptides. Currently in Phase II clinical trials, 
the γ-secretase modulator EVP-0962 has shown promise, as downstream effects such 
as Notch cleavage remain unaltered.122 Small molecule drugs have also been created 
to target BACE1, the first enzyme to cleave APP. However, Merck’s Verubecestat 
caused an increased risk of adverse effects132 and Lanabecestat developed by 
AstraZeneca in partnership with Eli Lilly and Company, failed in Phase III clinical trials 
for not meeting its primary endpoints.133 Other BACE inhibitors failed due to low BBB 
penetration, as well as causing liver toxicity.134 Further targets for intervention include 
Aβ-degrading proteases (Aβ-DPs), seeing as Aβ is continuously being degraded and 
produced in the brain.135 Improving degradation rates is one approach; inhibiting the 
inhibitors of Aβ-DPs is another. 
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More recently, there has been a shift towards passive immunotherapy.136 Monoclonal 
antibodies have the advantage of having high specificity, high affinity and low toxicity. 
These antibodies have been used for targeting hyperphosphorylated tau, microglial 
activation and Aβ aggregation. Many Aβ antibodies target the N-terminus of the 
protein, which is free in both monomeric and fibrillar forms. However, binding to the N-
terminus does not appear to provide therapeutic benefits. Antibodies such as 
Solanezumab,137,138 Crenezumab139 and Gantenerumab140 have been designed to 
bind to the central epitope of Aβ42, however Solanezumab trials have failed and 
closed, and initial trials for the other two have failed so far. Despite this, two Phase II 
Crenezumab trials and three Phase III Gantenerumab trials are currently ongoing.141 
One of the major challenges in this area is trying to develop an antibody that binds 
specifically to the soluble early aggregates, which are believed to be the most 
cytotoxic. Due to the heterogeneity of Aβ assembly, it remains unclear whether the C-
terminus is free in these early aggregates. BAN2401, currently in Phase III clinical 
trials, is believed to bind specifically to protofibrils.142 The pharmaceutical company 
Biogen took a different approach with aducanumab, a monoclonal antibody that 
selectively targets and dose-dependently reduces amyloid deposition, slowing down 
cognitive decline.43,143 Aducanumab failed to reach its primary endpoints in the last 
two Phase III clinical trials, however a new Phase III trial has been started.141  
Passive immunotherapies have also been engineered to target molecular chaperones 
in order to decrease the pathological aggregation of proteins. Another target is the 
insulin signalling pathway, since the insulin-degrading enzyme (IDE) plays a role in 
breaking down Aβ42, but is occupied in diabetics, preventing it from carrying out its 
physiological role. Other targets include microglial activation, genetic risk factors 
(ApoE, TREM2, APP) and inflammation. TNF inhibitors including monoclonal 
antibodies (e.g. Infliximab) and recombinant fusion proteins (e.g. Etanercept) have 
been developed to target neuroinflammation.82 
Gene therapies are also looking promising for AD, with recent advances in adeno-
associated virus (AAV) technology paving the way for new medicines.144 One of the 
main advantages of gene therapy for brain diseases is that it does not need to cross 
the blood-brain barrier like immunotherapies or small molecule drugs. In combination 
with the CRISPR/Cas9 genome editing tool, several early-onset and late-onset AD 
gene mutations are being investigated as points of intervention.145 A recent target for 
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gene therapy is CD33, which encodes for a microglial receptor, which is upregulated 
in AD and reduces the uptake and clearance of Aβ.146 Targeting CD33 in a mouse 
model of AD with gene therapy has shown significant reduction in amyloid beta 
accumulation and neuroinflammation.147 A more recent study has identified that 
antisense long non-coding RNA (lncRNA) can regulate and suppress production of tau 
in the brain.148 Gene therapies are currently being developed to enable the delivery of 
this lncRNA to brain cells to ultimately reduce the production of tau and therefore tau-
mediated toxicity. The first-in-human clinical trial for an AD gene therapy has recently 
entered Phase 1, which aims to deliver brain-derived neurotrophic factor (BDNF) 
packaged in an AAV to the entorhinal cortex and protect the cells from 
degeneration.149 Furthermore, biotech companies such as Mogrify, are developing 
technologies to aid ex vivo cell therapies and in vivo reprogramming therapies, using 
transcriptomic switches that allow the conversion of any human cell type to any 
other.150 Recent successes in gene therapy for other diseases suggest that this may 
also be a viable strategy for AD, however we still need a better understanding of the 
mechanisms underlying the disease in order to find better targets. 
1.7.1. Clinical Trials 
The R&D and clinical trial framework has changed drastically since the ‘thalidomide 
disaster’ of 1961, which had severe economic and regulatory ramifications on the 
pharmaceutical industry.151 With a rise in drug development costs and stricter 
regulations for drug approval, it is becoming increasingly more difficult for 
pharmaceutical companies to get their drugs through clinical trials, which can take 
several years to decades (Figure 9). Moreover, prior to testing on human patients, 
drugs need to be tested for safety and efficacy through a variety of assays. For this 
reason, the preclinical testing of drugs is integral to the development of a successful 
therapy with minimal undesirable side effects. Chapter 3 of this thesis focuses on the 
development and optimisation of a neuroinflammation assay for the preclinical testing 
of passive immunotherapies. 




Figure 9: Schematic of clinical trial timeline 
Clinical trials have a preclinical stage, which focuses on drug testing using cellular and animal models. 
In phases 1 – 4 of clinical trials the drug is administered to human patients. This process can take 
several years to decades.  
1.8. Challenges for AD Therapy 
Over the past three decades, there have been hundreds of failed AD clinical trials.152 
Despite our increased understanding of the disease pathology, there is still no drug 
that can stop or prevent disease progression. This is attributed to the disease’s 
multifaceted nature, with pathophysiological changes, symptoms and prevalence, 
varying greatly from patient to patient. This is further complicated by the fact that the 
majority of AD cases are expected to be mixed dementias, with the presence of 
neurodegenerative co-pathologies that include cerebrovascular disease and Lewy 
body disease.153 In fact, up to 33% of AD cases may have Lewy related 
pathology.154,155 In addition, diseases such as primary age-related tauopathies 
(PART), which are commonly observed in elderly patients, have similar neurofibrillar 
pathology to AD, increasing the challenge of AD diagnosis.156 Furthermore, AD has a 
long asymptomatic preclinical phase, where patients might not show cognitive 
dysfunction but can still have the disease.155,157 More reliable biomarkers and 
diagnostic tools are required in order to properly diagnose AD, as the distinction 
between healthy aging and preclinical AD remains unclear. Earlier intervention with 
existing therapeutics is currently under consideration.158 Moreover, a lack of follow up 
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of cognitive ability of patients (i.e. 10 years) after treatment could be contributing to 
the pre-emptive disqualification of some drugs from reaching the market.  
The complexity of AD and in fact all neurodegenerative diseases, make it very 
challenging to find good therapeutic targets. Protein targets are often present in 
multiple cell types with varying biological roles, so alterations to the target will often 
result in unwanted side effects. Fortunately, new methods for identifying cell-type-
specific targets are on the rise. One example is Cerevance’s Nuclear Enriched 
Transcript Sort sequencing (NETSseq) platform, which uses immunohistochemistry of 
human brain tissue to detect specific cell types, and then sorting their nuclei and 
performing RNA sequencing.159 This allows for the measurement of the expression of 
cell-type-specific genes, which has already lead to the discovery of several therapeutic 
targets for neurodegenerative diseases. 
Animal models of the disease, including mice, non-human primates, fruit flies, 
roundworms, and zebrafish, are commonly used in AD research, as they offer the 
advantage of allowing preclinical testing in vivo. They also allow for cognitive 
behavioural testing at more sensitive levels than would be possible with human 
patients. However, it is unclear how accurately these animal models reflect the actual 
disease pathology, as AD is a uniquely human disease. Genetic intervention is 
required to get these animal models to mimic the disease, and with most drugs being 
unsuccessful in clinical trials, the gold standard is working with human cells and 
tissue.160 
Recent advances in iPSC models of disease have enabled direct differentiation of 
iPSCs into various types of brain cells including neurons, astrocytes, microglia, 
oligodendrocytes, endothelial cells, and pericytes.161 Cells taken directly from AD 
patients have given rise to models with endogenous gene expression in vulnerable 
cell types. Furthermore, genetic manipulation with CRISPR/Cas9 allows for the 
insertion or removal of AD-specific mutations. The use of mass spectrometry in 
tandem with iPSC models has provided unprecedented insights into the regulation of 
specific proteins such as tau and APP/Aβ, and has enabled further validation of these 
models.162 Co-cultures of different cell types can help capture the complex interactions 
between cells, and iPSCs can even be grown in 3D cultures that can generate hallmark 
AD pathologies.163–166 Developments in iPSC differentiation protocols, improvements 
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in the reproducibility of iPSC-derived cell types, and the emergence of increasingly 
complex 3D co-culture systems, are giving rise to progressively better models of 
AD.161 
1.9. Sourcing clinically relevant aggregates 
It is widely accepted that small soluble Aβ42 aggregates are toxic through a variety of 
mechanisms, including the permeabilisation of cell membranes through non-specific 
binding, and by specific binding to pattern-recognising membrane receptors.60–63 This 
can lead to microglial activation and inflammation,167 a key player in AD 
pathology.93,168 Microglial activation increases as the disease progresses, and they 
become dystrophic at late stages.53 Through these toxic mechanisms, Aβ42 
aggregates have been shown to cause neuronal cell death, synaptic dysfunction, as 
well as cognitive impairment in AD patients and animal models of AD.36,37,177,169–176  
Despite only being a small subset of the overall protein aggregates found in brain 
tissue, it is believed that the soluble aggregates are responsible for most of the 
toxicity.178 Soluble aggregates have been found in the brain lysates of AD  
patients.179–181 However, these soluble aggregates occur at low concentrations and 
hence have been poorly characterised due to a lack of sensitive methods, with many 
more studies performed on synthetic or recombinant aggregates, since they are 
available in higher concentrations.182 It is still unclear how comparable endogenous 
aggregates from AD patients are to synthetic aggregates or to those from animal 
models.183,184 Far less research has been done on the aggregates in human CSF or 
extracted from post-mortem brain. Brain samples are generally homogenised and 
hence include large amounts of insoluble aggregates, which are largely inert, as well 
as soluble aggregates potentially complicating the interpretation of any analysis.  
To address these issues, there has been a recent effort to selectively extract the 
soluble aggregates from human brain tissue using minimally perturbative 
methods.178,185 The Klenerman group has previously developed a suite of sensitive 
methods with the potential to characterise aggregates and measure their properties.167 
These include size-separation of aggregates in these samples and measure their 
properties as demonstrated by experiments on CSF from AD patients.186 Soluble 
aggregate samples have previously been found to contain Aβ42 aggregates as 
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identified through western blotting, and can cause neurite length retraction on iPSC-
derived neurons, as well as block synaptic LTP.178,187 Furthermore, they can induce 
neuronal hyperactivation in mouse CA1 hippocampal neurons, as seen with two 
photon Ca2+ imaging.188,189 Soluble aggregate-induced toxicity is believed to be 
mediated partly by prion protein (PrP).190 However, there is no information about the 
size, structure, or inflammatory potential of the soluble aggregates extracted by 
soaking post-mortem brain nor how the aggregates differ between different brain 
regions. Chapter 4 of this thesis explores the implementation of our sensitive 
techniques to characterise soluble aggregates from early AD brains. 
1.10. Project aims 
Currently, there is no therapy or preventative strategy for AD. This is partly due to our 
limited understanding of the endogenous soluble aggregates in AD patients and their 
role in neuroinflammation, a key player in AD pathology.  
The aim of the first project (chapter 3) was to optimise a neuroinflammation assay that 
would test the inflammatory potential of toxic Aβ aggregates, using a BV2 microglial 
cell line. In conjunction with a liposome-permeability assay and an 
immunoprecipitation assay, this assay would act as a platform for the preclinical 
testing of passive immunotherapies, including a proprietary anti-Aβ42 antibody from 
MedImmune (now AstraZeneca).  
Most neuroinflammation studies have focused extensively on synthetic Aβ, and to a 
much lesser extent CSF or homogenised brain samples, which do not distinguish 
between soluble or insoluble aggregates.  
Therefore, the aim of the second project (Chapter 4) was to characterise the 
endogenous soluble aggregates from early AD patients, extracted through soaking 
brain tissue in artificial CSF buffer. Their size, morphology, inflammatory potential, 
neurotoxicity, and ability to permeate a lipid membrane, would be characterised using 
the neuroinflammation assay described in Chapter 3, a neurite-retraction assay, a 
liposome-permeability assay, AD-PAINT, AFM, and single-molecule pull-down 
(SiMPull) imaging. To assess regional variability in the brains of AD patients, soluble 
aggregates would be extracted from eight different regions. A better understanding of 
these aggregates and their mechanisms of action could shed some light on the events 
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2: Materials & Methods 
2.1. Sources of Aβ42 
Table 1: Sources of synthetic or recombinant Aβ42 
Supplier Buffer Cat. Code Synthetic/recombinant Purification 
AnaSpec SSPE AS-20276 Synthetic N/A 
Bachem NH4OH 4014447 Synthetic N/A 
Bachem HFIP 4014447 Synthetic N/A 
Abcam HFIP ab120301 Synthetic N/A 
Abcam GuHCl ab120301 Synthetic FPLC 
CoH GuHCl N/A Recombinant FPLC 
 
SSPE = saline-sodium phosphate-EDTA, NH4OH = ammonium hydroxide, HFIP = 1,1,1,3,3,3-
hexafluoro-2-propanol, GuHCl = guanidine hydrochloride, CoH = Chemistry of Health (Department of 
Chemistry, Cambridge), N/A = not applicable 
2.2. Preparation of synthetic Aβ42 
2.2.1. AnaSpec - SSPE 
AnaSpec Aβ42 was prepared as described previously.191–193 Briefly, lyophilised 
peptides were dissolved in saline-sodium phosphate-EDTA (SSPE) buffer (150 mM 
NaCL, 10 mM Na2H2PO4 x H2O and 10 mM Na2EDTA), adjusted to pH 12 using NaOH. 
This was followed by 30 min of sonication over ice (Bandelin Sonorex, Berlin, 
Germany) and then flash freezing into 10 μL aliquots. 
2.2.2. Bachem – NH4OH 
Bachem Aβ42 was prepared following manufacturer’s instructions. The peptide was 
dissolved in 1% v/v NH4OH/PBS and then diluted in PBS to a concentration of 
100 μg/mL. This was followed by vortexing gently for 1 min, then flash freezing into 
10 μL aliquots.  
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2.2.3. Bachem & Abcam - HFIP 
Abcam and Bachem Aβ42 were dissolved in HFIP and vortexed gently. The solution 
was then dried under a nitrogen stream, re-dissolved in 100% HFIP to a concentration 
of 1 mg/mL. After a 5-min sonication, they were dried under a nitrogen stream. The 
HFIP treatment was then repeated two more times and left to dry overnight in the fume 
hood. The samples were then flash frozen and split into 10 μL aliquots. 
2.2.4. Abcam - GuHCl 
Abcam Aβ42 lyophilised powder was dissolved in 6 M GuHCl and purified using a 
Superdex 75 10/300 GL column (GE Healthcare Bio-Sciences AB SE-751 84 Uppsala, 
Sweden), as previously described.194–196 This was carried out by Dr. Patrick Flagmeier. 
Protein concentration was then measured using a BCA assay.  
2.3. Preparation and purification of recombinant Aβ42 
Recombinant Aβ42 (MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) was 
expressed in the Escherichia coli BL21 Gold (DE3) strain and purified as described 
previously.194 This was done by members of the Chemistry of Health building, 
Cambridge. Monomeric Aβ42 was dissolved in 6 M GuHCl, then purified using a 
Superdex 75 10/300 GL column, as previously described.195,196 This was carried out 
by Dr. Patrick Flagmeier. Protein concentration was then measured using a BCA 
assay.  
2.4. Measuring Aβ42 aggregation kinetics  
Aggregation kinetics of the recombinant Aβ42 were measured using Thioflavin T 
(ThT), a benzothiazole salt amyloidophilic dye that fluoresces when bound to beta-
sheet structures.197 Samples of Aβ42 monomer were diluted in phosphate-buffered 
saline (PBS) and added to 20 μM ThT in low-binding Eppendorf tubes (Eppendorf AG, 
Hamburg, Germany). The samples were prepared on ice, to prevent any protein self-
assembly, and pipetted into a 96-well half-area, clear-bottom, low-binding 
polyethylene glycol coating plate (Corning 3881, Kennebuck ME, USA). The samples 
were loaded at 80 μL per well, at different concentrations of protein (usually 10 μM, 
5 μM, 2 μM, and 0 μM). The plate was then placed in a plate reader (Fluostar Omega; 
BMG Labtech, Ortenberg, Germany) at 37 °C, under quiescent conditions. 
Measurements were taken using the bottom reading mode (440nm excitation filter, 
480nm emission filter). Aggregation of Aβ42 for neuroinflammation and liposome 
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experiments was carried out in the plate reader in the same manner, excluding the 
addition of ThT, for desired times based on the previous ThT kinetics curves.  
2.5. AD brain tissue 
Fresh frozen brains from AD patients and non-AD controls (Table 2) were received 
whole from the Addenbrooke’s post mortem room, or from other centres around the 
country. Transport and consent details were reviewed and handled by the Cambridge 
Brain Bank. Processing of tissue was carried out in Addenbrooke’s hospital, where 
regions of interest were removed from the left cerebral hemisphere and frozen 
at -80 °C. The AD brains analysed in this study were diagnosed as being Braak 
stage III by histopathologists, based on tau protein pathology. 
2.5.1. Extraction of soluble aggregates from human brain tissue 
Soluble aggregates were obtained by following a previously established protocol with 
a few adaptations.178 Briefly, human brain tissue was chopped into 300 mg pieces 
using a razor blade and incubated with gentle agitation in 1.5 mL of artificial 
cerebrospinal fluid (aCSF) buffer (124 mM NaCl, 2.8 mM KCl, 1.25 mM NaH2PO4, 
26 mM NaHCO3; pH 7.4, supplemented with 5 mM EDTA, 1 mM EGTA, 5 μg/mL 
leupeptin, 5 μg/mL aprotinin, 2 μg/mL pepstatin, 20 μg/mL Pefabloc, 5 mM NaF) at 
4 °C for 30 min. Samples were centrifuged at 2,000 g(av) at 4 °C for 10 min and the 
upper 90% of the supernatant was collected and centrifuged at 14,000 g(av) for 110 min 
at 4 °C. The upper 90% of the supernatant was extracted and dialysed using Slide-A-
Lyzer™ cassettes (Thermo Scientific, Cat. 66330) with a 2 kDa molecular weight cut 
off, against 100-fold excess of fresh aCSF buffer with gentle agitation at 4 °C. Buffer 
was changed three times over the course of 72 hr dialysis. The prep was carried out 
under sterile conditions, using autoclaved LoBind Eppendorf tubes and pre-sterilised 
pipette tips to reduce endotoxin contamination. Samples were aliquoted into small 
volumes, snap frozen and stored in a -80 °C freezer and thawed only once prior to 
experimentation. This was optimised initially by me and Helen Dakin at Addenbrooke’s 
hospital and was then carried out solely by Helen for future batches. 
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2.5.2. Patient Information 
Table 2: Patient information & neuropathologic change scoring 

























-216 77 55 F 
Burkitt's 
Lymphoma III 2 3 1 
AD2 NP17
-194 71 70 M Pneumonia III 0 2 0 
AD3 NP17
-020 88 44 M 
End stage 
dementia III 1 3 1 
Control NP17




- 0 1 0 
 
AD = Alzheimer’s disease, C = control (non-AD), PM = post-mortem, PMI = post-mortem interval, 
M = Male, F = Female, NFT = Neurofibrillary tangles, NP = Neuritic plaques. 
Information from three Braak stage III AD patients and one non-AD patient whose brain tissue has been 
analysed in this study. Neuropathologic scoring is defined according to the National Institute on Aging 
– Alzheimer’s Association guidelines.198 
2.6. Neuroinflammation assay 
2.6.1. Cell culture 
BV2 cells derived from immortalised murine neonatal microglia (European Collection 
of Authenticated Cell Cultures) and immortalised wild type and TLR4-/- (NR-9458) 
macrophage cell lines (BEI Resources, USA), were all grown in T25 flasks in 
Dulbecco’s modified eagle medium (DMEM) (Gibco, Life Technologies, Cat. 21063-
029) with 10% v/v foetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO, Cat. 
F0926), 100 U/mL penicillin/100 μg/mL streptomycin (Gibco, Life Technologies, Cat. 
15140-122), 2 mM L-glutamine (Gibco, Life Technologies, Cat. 25030-024), 1% v/v 
sodium pyruvate and 1% v/v HEPES buffer. They were grown in a humidified 
environment, incubated at 37 °C, with 5% CO2, 95% air.  Filtered pipette tips were 
used throughout, that were sterile, and RNAase, DNAase, DNA and pyrogen free 
(STARLAB, S1126-7810). Cells were not used for experimentation past passage 8 to 
increase reproducibility of data. 
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2.6.2. Synthetic Aβ42 neuroinflammation 
Cells were plated in flat-bottom 48-well plates (Corning, Costar, Cat. 10065370) in 
DMEM (10% v/v FBS) at a density of 50,000 cells/well (300 μL per well). 24 hr after 
plating, the cells were washed with fresh pre-warmed (37 °C) media and kept in phenol 
red-containing DMEM 1% v/v FBS. Cells were treated with aggregated synthetic Aβ 
(Abcam) in a 1:4 dilution. LPS (Invivogen San Diego, CA, Cat. Tlrl-3pelps) at 10 ng/mL 
was used as a positive control. PBS in a 1:4 dilution was used as a vehicle control. 
The supernatant was collected every 24 hr for analysis and the wells were washed 
with fresh media and replaced with fresh solution. The supernatant was stored in a -
80 °C freezer and thawed only once before being measured with a mouse TNFα 
DuoSet ELISA (R&D Systems, MN, USA, Cat. DY410) using a plate reader 
(CLARIOstar, BMG Labtech, Ortenberg, Germany) at 450 nm. Experiments were 
carried out over 24-120 hr. Three wells were used for each condition to estimate 
variation.  
2.6.3. Brain-derived soluble aggregate neuroinflammation 
Cells were plated in flat-bottom 96-well plates (Corning, Costar, Cat. CLS3997) in 
DMEM (10% v/v FBS) at a density of 25,000 cells/well (150 μL per well). 24 hr after 
plating, the cells were washed with fresh pre-warmed (37 °C) media and kept in phenol 
red-containing DMEM 1% v/v FBS. Cells were treated with soluble aggregates in a 1:5 
dilution. LPS at 10 ng/mL was used as a positive control and aCSF buffer in a 1:5 
dilution was used as a vehicle control. The supernatant was collected every 24 hr for 
analysis and the wells were washed with fresh media and replaced with fresh solution. 
The supernatant was stored in a -80 °C freezer and thawed only once before being 
measured with a mouse TNFα DuoSet ELISA using a plate reader at 450 nm. 
Experiments were carried out over 96-120 hr. Three wells were used for each sample 
of soluble aggregates to estimate variation.  
2.7. Cytotoxicity measurements 
Cell supernatant collected from the neuroinflammation assay (BV2 cells) was stored 
at -80 °C. A lactate dehydrogenase (LDH) assay (Abcam, Colorimetric, Cat. 
ab102526) was used to detect the concentration of LDH (mU/mL) in the supernatants. 
Cells treated with RIPA lysis buffer (Thermo Scientific, Cat. 89900) were reported as 
100% cytotoxicity (100%), whereas vehicle control cells of the same density were 
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reported as 0% cytotoxicity. The supernatants were thawed only once before taking 
measurements.  
2.8. Preparation of cells for TNFα imaging 
This assay was based on previously established protocols, with several adaptations 
made to accommodate our BV2 cell line.199,200 Briefly, BV2 cells were plated at 
200,000 cells/mL on imaging slides (Ibidi, μ-Slide 4 well, Cat. 80426), 700 μL per well. 
They were then treated with 50 ng/mL LPS and 1 μM TNFα protease inhibitor-0 
(TAPI-0) for 2 hr, followed by fixation using 2% v/v paraformaldehyde (PFA) for 20 min 
at 4 °C. The cells were then blocked with blocking solution (PBS with 0.5% w/v BSA, 
4 μg/mL rat anti-mouse CD16/32 [Insight Biotechnology, FCγ II/III receptor block, Cat. 
553141], 5% v/v rabbit serum [Gibco, Cat. 16120099]) for 2 hr at room temp. Cells 
were then stained with 10 μg/mL rat anti-mouse TNFα antibody Alexa Fluor® 647 
antibody (BioLegend, Clone MP6-XT22, Cat. 506314) and washed four times with 
PBS before imaging. 
2.9. Immunoprecipitation experiments 
2.9.1. Synthetic Aβ42 
Immunoprecipitation was carried out as described previously, with a few 
adaptations.201 Briefly, Dynabeads® Protein A (Invitrogen, Cat. 10002D) and 
Dynabeads® Protein G (Invitrogen, Cat. 10004D), were mixed in a 1:1 ratio in low-
binding eppendorfs (Eppendorf AG, Hamburg, Germany), in conjunction with the 
proprietary MedImmune antibody and isotype control antibody (NIP-228), to pull down 
Aβ. The MedImmune antibody was added at a concentration of 0.2 nM and 20 nM, 
and NIP-228 at 20 nM to 2 nM monomeric Aβ (Abcam, GuHCl). Free-Aβ in solution 
was measured using an amyloid beta 42 human ELISA kit (Invitrogen, KHB3441). 
2.9.2. Soluble aggregate samples 
Immunoprecipitation with soluble aggregate samples was similar to using synthetic 
Aβ, with a few adaptations. Briefly, Dynabeads® Protein A and Dynabeads® Protein G 
were mixed in a 1:1 ratio in low-binding eppendorfs, in conjunction with an APP-
binding antibody (6E10, Mouse IgG1, Biolegend, Cat. SIG-39320) and isotype control 
antibody (Ultra-LEAF™, MG1-45, Biolegend, Cat. 401408) to pull down Aβ-containing 
fragments. The antibodies were added at a concentration of 20 μg/mL. 400 μL of 
soluble aggregate samples from the HPC and VAC regions were then added to the 
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mix. The eppendorfs were placed on a magnetic rack to pull down the magnetic beads, 
along with the antibody and binding targets. The neuroinflammation assay was then 
carried out on soluble aggregates with or without immunodepletion of Aβ-containing 
fragments.  
2.9.3. Antibodies used for immunoprecipitation experiments 
Table 3: Antibody information 








IgG1 Aβ 1-42 Human Human 
25 mM Histidine, 7% 
sucrose, pH 6.0 MedImmune 
NIP228 IgG1 
Isotype 
control Human Human 
25 mM Histidine, 7% 
sucrose, pH 6.0 MedImmune 
6E10 IgG1 
APP or  
Aβ 1-16 Mouse Human PBS BioLegend 
MG1-45 IgG1 
Isotype 
control Mouse Human PBS BioLegend 
4G8 IgG2b Aβ 17-24 Mouse Human, dog PBS BioLegend 
A15126D IgG2b 
α-synuclein 
117-122 Mouse Human PBS BioLegend 
 
Table of the antibodies used for immunoprecipitation experiments. 
2.10. Neurite retraction assay 
2.10.1. Primary mouse hippocampal neurons 
Primary mouse hippocampal neurons were extracted from mouse pups and plated in 
96-well plates (IncuCyte® ImageLock, 4379) at a density of 30,000 cells/well in 
neurobasal media (supplemented with 1% v/v Pen/Strep, 1% v/v Glutamax, 2% v/v 
B27, 1% v/v N2). A 50% media change (25% fresh media, 25% sample) was carried 
out after 72 hr. The plate was placed in IncuCyte® S3 live cell imaging system and 
monitored for 84 hr. Four images were taken per well, every four hr. Neurite length 
was measured using NeuroTrack software with the following settings: Segmentation 
Mode: Brightness; Segmentation Adjustment: 1; Min Cell Width (μm): 7; Area (μm2) 
min: 95; Neurite Filtering: Best; Neurite Sensitivity: 0.55; Neurite Width (μm): 1. 
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2.10.2. Red Lentivirus synapsin promoter 
Primary mouse hippocampal neurons were transduced with the IncuCyte® Neurolight 
Red Lentivirus (Sartorius, 4807) following the manufacturer’s instructions with a few 
adaptations.  Briefly, the lentivirus reagent was added to the cells 4 hr after plating, 
followed by a 95% media replacement 24 hr later. A 50% media replacement then took 
place every 3 days.  
2.10.3. LUHMES cells 
Lund Human Mesencephalic (LUHMES) cells were purchased from the American 
Type Culture Collection (ATCC) (Cat. CRL-2927) and were cultured according to the 
ATCC guidelines. Briefly, the cells were grown in a T75 flask pre-coated with 50 μg/mL 
poly-L-ornithine (Sigma, Cat. P3655) and 1 μg/mL Human Fibronectin (Sigma, Cat. F-
0895) in DMEM:F12 (Invitrogen, Cat. 31330038), supplemented with L-glutamine, N2 
supplement (Invitrogen, Cat. 17502-048), and basic recombinant human Fibroblast 
Growth Factor (b-FGF) (Sigma, Cat. F0291). Experiments were carried out after 4 
days of differentiation in DMEM:F12 medium containing N2 supplement, 2 ng/mL 
human recombinant GDNF (R&D Systems, Cat. 212-GD), 1 mM dibutyryl cAMP 
(Sigma, Cat. D0260) and 1 μg/mL tetracycline (Sigma, Cat. 87128). Cells were plated 
at a density of 1 x 105 cells/mL (100 μL per well) and treated with soluble aggregates 
in a 1:5 dilution. Lipopolysaccharide (LPS) (Invivogen San Diego, CA, Cat. Tlrl-3pelps) 
at 10 ng/mL was used as a positive control and aCSF buffer in a 1:5 dilution was used 
as a vehicle control. The plate was placed in an IncuCyte® S3 live cell imaging system 
right after treatment and monitored for 48 hr. Four images were taken per well (~600 
cells per field of view), every hour, with three wells per condition, totaling ~7,200 cells 
imaged per condition per experiment. Two biological replicates were carried out. 
Neurite length was measured using NeuroTrack software with the following settings: 
Segmentation Mode: Brightness; Segmentation Adjustment: 0.7; Adjust size (pixels): 
1; Min Cell Width (μm): 25; Area (μm2) min: 500; Neurite Filtering: Best; Neurite 
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2.11. Liposome-permeabilisation assay 
The liposome-permeabilisation assay was carried out by Dr Patrick Flagmeier, Dr Suman De, and Zengjie Xia. 
The membrane permeabilisation assay was performed as described previously.194  
Briefly, liposomes composed of 16:0-18:1 PC and 18:1-12:0 biotin PC (100:1) (Avanti 
Lipids), with an average diameter of 200 nm, were prepared using extrusion and 
freeze-thaw cycles. Vesicles filled with 100 μM Cal-520 dye were bound to a glass 
surface coated with PLL-g-PEG and PLL-g-PEG biotin (10:1) (Susos AG), via a biotin-
neutravidin linkage. A series of 9 different images were taken of 30 μL Ca2+ containing 
buffer alone to measure the background for each set (Fblank). The same volume of 
soluble aggregates was then incubated on the glass coverslip for 15 min and imaged 
in the exact same fields of view (Fsample). The same fields of view were then re-imaged 
after the addition of 10 μL of ionomycin (Fionomycin). By first determining the intensity of 
each individual vesicle, the average Ca2+ influx was calculated using the following 
formula: 
 	
 – 	 − 	 × 100% 
Imaging was carried out using a home-built total internal reflection fluorescence (TIRF) 
microscope, fitted with a 488 nm laser (Toptica, iBeam smart, 200 mW, Munich, 
Germany), which was used to excite the samples. The laser beam was expanded and 
collimated using two Plano-convex lenses on the back-focal plane of the 60X, 1.49NA 
oil immersion objective lens (APON60XO TIRF, Olympus, product number N2709400) 
to a spot of adjustable diameter. An EmCCD camera (Photometrics Evolve, EVO-512-
M-FW- 16-AC-110) was used to image the dye fluorescence emissions collected by 
the objective. 
2.12. Aptamer-DNA PAINT (AD PAINT) imaging 
AD PAINT imaging was carried out by Dr John Danial and Dr Jason C. Sang. 
AD PAINT imaging was performed as described previously, with a few adaptations.202 
Briefly, round slides were cleaned for 1 hr with argon plasma. A multiwell chamber 
coverslip (CultureWell CWCS-50R-1.0) was then added to the slide. The wells were 
cleaned with PBS 1% v/v Tween 20 for 1 hr before adding 5x diluted soluble aggregate 
samples in PBS for 1 hr. The wells were washed twice with fresh PBS and replaced 
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with imaging mix (2 nM imaging strand (sequence CCAGATGTAT-CY3B), and 
100 nM aptamer-docking strand (sequence GCCTGTGGTGTTGGGGCGGGTGC-
GTTATACATCTA) in PBS). All buffers were passed through a 0.02 μm filter 
(Anotop25, Whatman, Cat. 516-1501) before use. Prior to imaging, a clean coverslip 
was used to seal the wells in order to prevent evaporation. Imaging was performed on 
a home-built TIRF microscope using a 1.49 N.A., 60x objective (UPLSAPO, 60X, 
TIRF, Olympus) and a perfect focus system. More details about the microscope set 
up and data analysis are described in Whiten et al.202  
2.13. Atomic force microscopy (AFM) imaging 
AFM imaging was carried out by Dr Francesco Simone Ruggeri. 
Brain-derived soluble aggregates were diluted 10x in PBS buffer and imaged on 
freshly cleaved mica substrates using AFM. 10 μL diluted samples were deposited on 
the substrate at room temperature. The samples were incubated for 10 min, followed 
by rinsing with 1 mL milliQ water. The samples were then dried using a gentle flow of 
nitrogen gas. AFM maps of 3-D morphology of all the samples were acquired in regime 
of constant phase change, with 2-4 nm/pixel resolution using a NX10 (Park Systems, 
city, South Korea) operating in non-contact mode.203 This set up was equipped with a 
silicon tip with a nominal radius of <10 nm and spring constant of 5 N/m (PPP-NCHR). 
For each sample, we scanned an area between 250-500 μm2. The lower limit was 
used for samples where aggregated species were found and the upper limit for the 
samples without aggregates. Scanning Probe Image Processor (SPIP) (version 6.7.3, 
Image Metrology, Denmark) software was used for image flattening and single 
aggregate statistical analysis. The average level of noise for each image was 
measured using SPIP software and was smaller than 0.1 nm.204 All the measurements 
were performed at room temperature. 
2.14. Single-molecule pull-down (SiMPull) imaging 
SiMPull imaging was carried out by Derya Emin, Yu P. Zhang, and Dr Evgenia Lobanova 
Glass coverslips covalently mounted with polyethylene glycol (PEG) were used for 
SiMPull experiments. Coverslip preparation was carried out as described previously, 
with a few modifications.205 Briefly, glass coverslips (26X76 mm, thickness 0.15 mm, 
Thermo Scientific) were washed ultrasonically (cleaner USC100T, VWR), in a series 
of solvents (10 min in 18.2-MΩ/cm Milli-Q water, 10 min in acetone, then 10 min in 
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methanol (MeOH)). The washed coverslips were then etched by 1 M potassium 
hydroxide (KOH) under 20 min ultrasonication and rinsed with a series of solvents 
(MeOH, 18.2 MΩ-cm Milli-Q water, then MeOH). The processed coverslips were dried 
using nitrogen flow and cleaned with argon plasma for 15 min (Femto Plasma Cleaner; 
Diener Electronic). The coverslips were then silanised with 5 mL of 3-aminopropyl 
triethoxysilane (Fisher Scientific UK, Cat. 10677502), 8.3 mL acetic acid (AcOH) in 
166.7 mL MeOH for 20 min, with 1 min ultrasonication at the start and mid-point of 
reaction (10 min after the start point). The silanised coverslips were then rinsed in 
MeOH, 18.2 MΩ-cm Milli-Q water, followed by MeOH and dried using nitrogen flow. 
50-well polydimethylsiloxane (PDMS) gaskets (Sigma, GBL103250-10EA) were then 
attached to the cleaned and silanised coverslips. To passivate the wells, 9 µl of a 100:1 
aqueous mixture of succinimidyl valeric acid PEG (MPEG-SVA-5000) (110 mg/mL, 
Laysan Bio Inc.) and Biotin-PEG-SVA-5000 (1.1 mg/mL, Laysan Bio Inc.) were added, 
with additional 1 µL of 1 M sodium bicarbonate (NaHCO3) (pH 8.5). The coverslips 
were incubated with PEG solution overnight in a humid chamber and then rinsed with 
18.2 MΩ-cm Milli-Q water and dried with nitrogen flow. The passivated wells were 
treated by adding 9 µl of MS(PEG)4 methyl-PEG-NHS-Ester (10 mg/mL, Thermo 
Scientific, Cat. 22341), with additional 1 µL of 1 M NaHCO3 (pH 8.5). The coverslips 
were incubated with PEG solution overnight in a humid chamber and then rinsed with 
18.2 MΩ-cm Milli-Q water and dried with nitrogen flow. PEGylated glass coverslips 
were stored in a desiccator at −20 °C until needed. 
For the experiment, neutravidin (0.2 mg/mL) was added to the coverslip for 5 min, 
followed by two wash steps with 0.05% (v/v) PBST and once with 1% (v/v) PBST. 
Afterwards biotinylated 6E10 (Signet, Cat. 9340-02, 10 nM) was added for 10 min, 
followed by two wash steps with 0.05% (v/v) PBST and once with 1% (v/v) PBST. The 
soluble aggregates were added for at least 1 hr at room temperature followed by two 
wash steps with 0.05% (v/v) PBST and once with 1% (v/v) PBST. The coverslips were 
blocked using blocking solution containing 0.1% (w/v) bovine serum albumin (BSA) 
(Thermo Scientific, Cat. AM2616), 10% (v/v) salmon sperm (Thermo Scientific, Cat. 
15632011) and 0.1% (v/v) PBST for 1 hr at room temperature. The coverslips were 
then incubated with labelled 6E10 (cat. 80302, 500 pM) for 45 min, followed by three 
washing steps with 0.05% (v/v) PBST. To properly seal the imaging chamber and 
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prevent evaporation, 3 μL of PBS was added to each well and sandwiched with a 
second coverslip. 
To determine the number of fluorescent molecules in each image, a z-stack was 
generated in ImageJ. The images were cropped to 380 x 380 pixels and the contrast 
was adjusted. Using the negative control as a baseline, a threshold was applied to all 
images, and single molecules above this threshold were counted. 
2.15. Primary cell culture 
2.15.1. Culturing of rat primary astrocytes for neuroinflammation assay 
Primary rat astrocytes were collected from 1-7 days old Sprague-Dawley rat pups, 
which were grown and culled at the Department of Veterinary Medicine, Cambridge. 
The protocol for harvesting and culturing this mixed glial prep was carried out as 
previously described with slight modifications.206,207 Briefly, the brain was removed and 
placed in a petri dish filled with Hank’s balanced salt solution (HBSS). Then the brain 
was carefully rolled onto lens paper to remove visible blood vessels and pressed 
through a filter into a falcon tube using a spoon. 2 mL of media with 10% v/v Hyclone™ 
FBS (GE Life Sciences, Cat. SV30160.03) was added onto the filter. The remaining 
tissue was then pushed through the filter, followed by the addition of 3 mL of media. 
The falcon tube was centrifuged at 1,500 g(av) for 5 min. The supernatant was removed 
and re-suspended in 30 mL of media, followed by careful trituration. Another 15 mL of 
media was then added, and the solution was plated out in three T75 flasks, 15 mL per 
flask. These were then incubated at 37 °C, 5% CO2. The mixed-glial prep was 
composed almost entirely of astrocytes 2 weeks after plating. 
2.15.2. Culturing of human primary astrocytes for neuroinflammation assay 
Human primary astrocytes were purchased from ScienCell Research Laboratories 
(SC-1800) (1 x 106 cells/vial) and provided by our collaborators at the Institute of 
Neurology, University College London. These cells were grown in astrocyte medium 
(ScienCell Research Laboratories, SC-1801), in T75 flasks, in an incubator at 37 °C, 
5% CO2.  
2.15.3. Culturing of mouse primary neurons for neurite retraction assay 
The brains from the mouse embryos were removed and placed into a petri dish 
containing HBSS. The hippocampi and cortices were isolated, the meninges removed, 
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and the tissue was transferred to a falcon tube with 15 mL HBSS on ice. 500 μL of 
trypsin was added to the falcon tube and incubated at 37 °C in a water bath for 15 min. 
Under a sterile fume hood, the HBSS/trypsin solution was replaced with fresh pre-
warmed neurobasal media (NBM) and washed twice. The tissue was then 
resuspended in 1 mL NBM (Thermo Fisher Scientific, cat. 21103049) supplemented 
with with 2% v/v B27 (Thermo Fisher Scientific, 17504044), 1% v/v N2, 1% v/v 
Pen/Strep and 1% v/v GlutaMax. The cells were then counted and plated in 96-well 
plates (Greiner, 655090) coated with Poly-D-Lysine (PDL) (Greiner, A3890401). There 
was a 30% media change at 4 DIV, then every 2-3 days after. This was done by Robyn 
McAdam at AstraZeneca. 
2.15.4. Culturing of mouse primary microglia for neuroinflammation assay 
Brains were removed from the mouse pup heads (using scissors and forceps) and 
kept in growth medium (DMEM with GlutaMax supplemented with 10% v/v FBS and 
pen/strep, on ice in a petri dish). The meninges were removed by rolling on sterile filter 
paper. All brains were placed in fresh growth medium and triturated vigorously using 
a 10 mL pipette up and down a 50 mL falcon tube, for 5-10 min, then filtered through 
a cell strainer (40 micron). They were then centrifuged at 250 g(av) for 2 min and the 
cells were resuspended in a total volume of 40 mL per flask, with 4 brains per flask. 
Cells were left for 1 week to adhere and for the astrocyte layer to proliferate. The 
microglia gradually form a layer on top of this confluent layer. To increase the number 
of microglia in the mixed glial prep, 5 ng/mL murine GM-CSF (from R+D systems) was 
added to enhance microglia proliferation. The cells were left in the GM-CSF-enriched 
medium for 1 week. Microglia were removed by “shaking” overnight in an orbital shaker 
incubator (37 °C, 100 revolutions per minute). HEPES was added to the medium 
(50 mM final) just prior to shaking cells overnight. Following shaking, the supernatant 
was collected from the flasks (containing the dissociated microglia). The microglia 
were centrifuged at 250 g(av) for 2 min and resuspended in medium without GM-CSF, 
counted, and plated in 96-well plates. 
2.16. Immunostaining for neurons, astrocytes, and microglia 
Cells were washed with PBS (50 μL per well for a 96-well plate) and fixed for 10 min 
at room temperature with a solution of 4% PFA v/v in PBS (50 μL per well for a 96-
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well plate). The cells were washed again with PBS before adding the following primary 
antibody solutions: 
Table 4: Table of primary antibodies used for immunostaining 
Antigen Description Cell Type 
Working 
concentration  
Host Species Source 
NeuN 
Expressed in neuronal 
nuclei 





exclusively in neurons 
and testis cells 





expression among glial 
cells 











The primary antibodies were prepared in PBS supplemented with 0.2% v/v Tween 20. 
The primary antibody solution was incubated in the plate overnight at 4 °C, followed 
by three washes with PBS (100 μL per well for a 96-well plate). The following 
secondary antibody solutions were then added: 
Table 5: Table of secondary antibodies used for immunostaining 
Antibody Working concentration  Host Species Source 
Anti-mouse 488 (FITC) 0.2 μg/mL Goat 
Invitrogen 
A11001 
Anti-rabbit 647 (Cy5) 0.2 μg/mL Goat 
Invitrogen 
A21244 
Anti-rabbit 488 (FITC) 0.2 μg/mL Goat 
Invitrogen 
A11034 




The secondary antibodies were prepared in PBS supplemented with 0.2% v/v Tween 20. 
The secondary antibody solution was incubated at room temperature for 1 hr, before 
being removed and replaced with 40 μL of Hoechst stain in blocking solution (1:10000) 
and incubated for 10 min at room temperature. The cells were washed 3 times with 
PBS (100 μL per well for a 96-well plate) and imaged with an Olympus epifluorescence 
microscope. 
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2.17. Protein measurements 




Product code Source 
TNFα ELISA Mouse DY410 R&D Systems 
Aβ42 ELISA Human KHB3441 Invitrogen  
Aβ42 ELISA (ultrasensitive) Human KHB3544 Invitrogen  






TNFα, IL-1β, IL-6, MCP-1, 
RANTES, MIP-1a, MIP-1b 
ELISA - multiplex Mouse 
Customised on 
website 






Various commercially available kits were used to measure the concentrations of various protein targets. 
2.17.1. Western blot 
Samples were diluted in Bolt LDS Sample Buffer (Thermo Fisher Scientific, Cat. 
B0008), Bolt Reducing Agent (Thermo Fisher Scientific, Cat. B0009), and distilled 
water to appropriate concentration. They samples were then heated at 70 °C for 
10 min. A pre-cast 1.0 mm 4 - 12% gradient 15-well Bolt Bis-Tris Plus gel (Thermo 
Fisher Scientific, Cat. NW04125BOX) was set up in a Mini Gel Tank (Thermo Fisher 
Scientific) with SDS Running Buffer (50 mL of 20X Bolt MES SDS Running Buffer 
[Thermo Fisher Scientific, Cat. B0002], 950 mL of distilled water, and 2.5 mL of Bolt 
Antioxidant [Thermo Fisher Scientific, Cat. BT0005]). A Chameleon Duo pre-stained 
Protein Ladder (LI-COR, Cat. 928-60000) was loaded into the appropriate wells, and 
electrophoresis was set to run at 200 V. The proteins separated on the gel were 
transferred onto a low-fluorescence PVDF membrane using the iBlot 2 Dry Blotting 
System (Thermo Fisher Scientific) with iBlot 2 Transfer Stacks (Invitrogen, Cat. 
IB24001). The membrane was blocked using 10 mL of Intercept Blocking Buffer in 
PBS (LI-COR, Cat. 927-90001) for 1 hr at room temperature, and then washed with 
PBS supplemented with 0.2% Tween (v/v), and incubated with 6E10 primary antibody 
(BioLegend, Cat. 803004) at 1 μg/mL, diluted in blocking buffer, overnight at 4 °C on 
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a shaker. This was then washed and replaced with IRDye 800CW Donkey anti-Mouse 
IgG secondary antibody (LI-COR, Cat. 926-32212) diluted 1:10000 in blocking buffer 
and incubated for 1 hr in room temperature on a shaker. The membrane was then 
washed and imaged on an Odyssey CLx Imaging System (LI-COR Biosciences). 
2.18. Statistical analysis 
GraphPad Prism v9 was used to carry out statistical analyses for all experimental data 
except for AFM data. Unpaired two-tailed t-tests have been used to test the null 
hypothesis, in cases where two independent, normally distributed samples needed 
comparing. An alpha value of (p < 0.05) was chosen to represent significant 
differences in the data (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001). In cases where 
more than two independent variables needed comparing, a one-way analysis of 
variance (ANOVA) was used. This was followed by a Tukey post hoc test when 
comparing the mean of each variable to the mean of every other variable, or a Dunnett 
post hoc test when comparing the mean of each variable to the mean of one control 
variable. Kolmogorov-Smirnov tests have been used when comparing non-normally 
distributed cumulative distributions (AD PAINT and SiMPull data). To assess the 
variability between independent repeats of the experiment and between patients, 
multiple comparisons tests were carried out. Individual statistical values are reported 
in the figure legends. 
Scanning Probe Image Processor (SPIP) software was used for image flattening and 
single aggregate statistical analysis for AFM imaging data. AFM data was plotted using 
OriginPro® 2021. Mann-Whitney two-tailed tests were used to compare the medians 
of the non-normally distributed data sets. Individual statistical values are reported in 
the figure legends. 
Patient samples were blinded prior to experimentation and were only unblinded after 
data analysis. Region selection for all imaging experiments was automated, ensuring 
randomisation and elimination of human bias. Furthermore, data analysis parameters 
(e.g. thresholding) were kept consistent within each data set. Data gathered by ELISA 
or MSD was analysed using MARS data analysis software. A four-parameter fit was 
fitted to the data, as per the kit manufacturer’s instructions. Schematics/graphics were 




3: Preclinical Testing of Passive Immunotherapies 
3.1. Introduction 
It is widely reported that Aβ aggregates can cause neuroinflammation, a key player in 
AD pathology. The sustained activation of glial cells leads to the overproduction of 
proinflammatory cytokines and chemokines, which contribute to neurodegeneration. 
TNFα is the cytokine most strongly associated with AD pathology, due to its 
involvement in the aggregation of Aβ42. 
There are multiple ways of assessing neuroinflammation in vitro. These include 
performing immunocytochemistry to image specific glial markers, using quantitative 
real-time PCR to measure gene expression of inflammatory markers, performing live-
cell phagocytosis or cell viability assays, and by measuring the release of cytokines 
and chemokines from stimulated glial cells using ELISA or Western blotting.167,208–210 
These assays are generally performed on microglial or astrocytic cell lines, primary 
cells, or iPSC-derived cells. Primary and iPSC-derived cells are generally more 
clinically relevant as they better recapitulate endogenous glial cell properties, however 
cell lines are more commonly used as they are easier to obtain and culture, while still 
maintaining important glial properties.211  
In this chapter, a neuroinflammation assay has been optimised that allows the 
measurement of TNFα production from an Aβ42-treated microglial cell line using an 
ELISA. This assay can be employed as a preclinical platform for drug testing against 
Aβ-mediated inflammation. A proprietary anti-Aβ42 antibody from MedImmune (now 
AstraZeneca) has undergone preclinical testing using a variety of assays to measure 
its effects on Aβ42-driven inflammation and liposome permeability. 
3.2. Neuroinflammation assay 
For the optimisation of the neuroinflammation assay, a widely reported microglial-like 
cell line was used due to its convenience and ease of handling. BV2 is a well-
characterised, immortalised murine microglial cell line that is often used when primary 
microglia are not available. Similar to primary microglia, they are widely reported to 
produce an inflammatory response to LPS, show physiological regulation of nitric 
oxide (NO) production, respond to IFN-γ from T-cells and can stimulate other glial 
cells.212 The experimental set up of the neuroinflammation assay was as follows: 




Figure 10: Schematic of neuroinflammation assay 
Aggregated synthetic Aβ42 was added in a 1:4 dilution to BV2 cells, triggering proinflammatory cytokine 
release. Levels of TNFα in the cell supernatant were then measured by ELISA, acting as a marker of 
inflammation. A vehicle control was always included as a negative control, and LPS was added as a 
positive control for inflammation.  
3.2.1. LPS optimisation 
LPS, which is found in the outer membrane of gram-negative bacteria, is often used 
as a positive control for inflammation experiments as it causes TLR4 activation. To 
determine the appropriate concentration of LPS to use for the neuroinflammation 
assay, an LPS dose-response was carried out. The cell supernatant was also tested 




Figure 11: LPS dose-response 
(a) Standard curve showing the linear range of the TNFα assay (~62.5 - 2,000 pg/mL). A 4-parameter 
fit has been used to calculate the levels of TNFα in the samples. (b) BV2 cells were treated with various 
concentrations of LPS for 24 hr. BV2 cells were plated at 50,000 cells/well in 48 well plates. Vehicle 
control was DMEM + endotoxin-free water used to dilute the LPS. TNFα production was measured by 
ELISA. Error bars represent the mean ± SD of three wells. (One-way ANOVA: F(6 14) = 12.05, 
p < 0.001. Post hoc Tukey test: 1 vs 10: p = 0.049; 10 vs 50: p = 0.89; 10 vs 100: p = 0.98; 10 vs 250: 
p > 0.99; 10 vs 500: p > 0.99; 50 vs 100: p > 0.99; 50 vs 250: p = 0.98; 50 vs 500: p = 0.99; 100 vs 250: 
p > 0.99; 100 vs 500: p > 0.99; 250 vs 500: p > 0.99). (c) LDH cytotoxicity assay used on cell 
supernatant to measure cell viability. Error bars represent the mean ± SD of three wells. (One-way 
✱
a b c 
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ANOVA: F(6, 14) = 8.502, p < 0.001. Post hoc Dunnett test: Vehicle vs 1: p = 0.98; Vehicle vs 10: 
p = 0.89; Vehicle vs 50: p = 0.02; Vehicle vs 100: p = 0.02; Vehicle vs 250: p = 0.002; Vehicle vs 500: 
p < 0.001). 
LPS at 10 ng/mL caused a significant increase in TNFα response. However, increasing 
the concentration past 10 ng/mL had no significant effect, similar to what has been 
previously reported with another microglial cell line.213 Furthermore, concentrations 
higher than 10 ng/mL caused significant cell death. LPS-induced BV2 cell death has 
been previously reported using MTT assays measuring mitochondrial dysfunction,  
fluorescence microscopy using calcein (for live cells) and ethidium homodimer 
(nuclear stain for dead cells), and Greiss assays for measuring iNOS and NO 
production.214 10 ng/mL was therefore selected as the optimal LPS concentration for 
future experiments. 
3.2.2. FBS optimisation 
Initial experiments had relatively high basal levels of TNFα after 24 hours, ~200 pg/mL 
(Figure 11a). This suggested that the cells were stressed, most likely due to the 
presence of endotoxin contamination, which could compromise the integrity of the 
data. The FBS in cell media is a potential source of endotoxin, with endotoxin levels 
varying greatly from batch-to-batch and between suppliers, and can trigger an 
inflammatory response in macrophages.215 Two types of FBS, HyClone™ 
(SV30160.03) and Sigma (F0926) were therefore tested to determine whether FBS 
endotoxin was contributing to the high basal levels of TNFα.  
Furthermore, it is common to reduce or completely remove serum before experiments 
involving cytokine measurements.75 The reason for this is that FBS contains a wide 
range of proteins that could potentially elicit an inflammatory response. In addition, 
FBS increases cell proliferation, which can cause over confluency in longer 
experiments. To determine the optimal concentration of FBS for these experiments, 








Figure 12: FBS optimisation 
BV2 cells were plated in three serum conditions: serum-free, 1% FBS and 10% FBS. Two types of FBS 
were tested, HyClone™ FBS and Sigma FBS. TNFα production was measured by ELISA after 24 hr. 
Prior to experimentation, the cells were grown in 10% HyClone™ FBS supplemented DMEM for two 
weeks. BV2 cells were plated at 50,000 cells/well in 48 well plates. Error bars represent the mean ± SD 
of three wells. (One-way ANOVA: F(4, 10) = 0.4246, p = 0.79. Post hoc Tukey test: Serum-free vs 1% 
HyClone: p = 0.86; Serum-free vs 10% HyClone: p > 0.99; Serum-free vs 1% Sigma: p = 0.93; Serum-
free vs 10% Sigma: p > 0.99; 1% HyClone vs 10% HyClone: p = 0.83; 1% Sigma vs 10% Sigma: 
p > 0.99). 
Both HyClone™ and Sigma FBS induced similar levels of TNFα production. 
Furthermore, there was no significant difference between the inflammation produced 
from cells plated in 10% FBS, 1% FBS, or serum-free conditions. This suggested that 
FBS-endotoxin may not be the source of the elevated basal levels of TNFα.   
Other potential sources of endotoxin contamination included non-sterile cell culture 
reagents and sub-optimal cell culture practices. Non-filtered pipette tips and benchtop 
tubes were replaced with autoclaved pre-sterilised filtered pipette tips and LoBind 
Eppendorf tubes. Cell media was made fresh every two weeks instead of monthly and 
supplemented with HEPES buffer to reduce changes in pH. To confirm whether these 
conditions had an effect on basal TNFα levels, the FBS experiments were repeated 
with and without the improved sterile conditions. 
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Figure 13: Further FBS optimisation with and without improved sterile conditions 
BV2 cells were plated in three serum conditions: serum-free, 1% FBS and 10 % FBS. Two types of FBS 
were tested, HyClone™ FBS and Sigma FBS. TNFα production was measured by ELISA after 24 hr. 
Prior to experimentation, the cells were grown in 10% HyClone™ FBS supplemented DMEM for two 
weeks. BV2 cells were plated at 50,000 cells/well in 48 well plates. Solid filled bars represent the 
conditions with the improved sterile changes (‘sterile’), and the striped bars represent the conditions 
without (‘non-sterile’). Error bars represent the mean ± SD of three wells. (One-way ANOVA: F(0, 
20) = 82.91. Post hoc Tukey test: Serum-free (non-sterile) vs Serum-free (sterile): p < 0.001; 1% 
HyClone (non-sterile) vs 1% HyClone (sterile): p < 0.001; 10% HyClone (non-sterile) vs 10% HyClone 
(sterile): p < 0.001; 1% Sigma (non-sterile) vs 1% Sigma (sterile): p < 0.001; 10% Sigma (non-sterile) 
vs 10% Sigma (sterile): p < 0.001). 
As seen previously (Figure 12), there was no significant difference between the three 
different FBS concentrations, or the two different types of FBS. However, the 
implementation of the improved sterile conditions significantly reduced the basal TNFα 
response. This suggested that the high basal levels of TNFα were due to non-sterile 
conditions and reagents (non-filtered pipette tips and non-autoclaved Eppendorf 
tubes), not the FBS type or concentration.  
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3.2.3. Post-experimental handling of samples 
Centrifugation and/or sterile filtering of cell supernatant to remove cell debris is often 
carried out prior to sample analysis.216 To determine whether these steps were 
necessary before ELISA analysis, the frozen supernatant from an experiment where 
BV2 cells were treated with 1 ng/mL LPS and 10 ng/mL LPS for 24 hours, was 
collected and passed through these conditions. An ELISA was then carried out to 
detect whether these conditions had an effect on TNFα measurements. 
 
Figure 14: Centrifugation and sterile filtering 
Cell supernatants from a previous experiment were either centrifuged at 14,000 g(av) at 4 °C for 10 min, 
or filtered with a 0.22 μm sterile filter, or both. Supernatant was thawed only once before ELISA analysis. 
Error bars represent the mean ± SD of three technical repeats. (One-way ANOVA for LPS 1 ng/mL: 
F(3, 8) = 0.1482, p = 0.93. One-way ANOVA for LPS 10 ng/mL: F(3, 8) = 0.5774, p = 0.65). 
Centrifuging and/or sterile filtering cell supernatant before ELISA analysis did not 
appear to affect TNFα measurements. This suggested that cell debris and other cell 
contents did not impede the ELISA TNFα antibody from binding to its target protein, 
or generally interfere with the assay. For this reason, centrifugation and sterile filtering 
of cell supernatants before ELISA experiments was not deemed necessary and was 
not carried out for future experiments. 
Before moving to more clinically relevant samples, synthetic Aβ42 aggregates were 
used for assay optimisation, due to their availability at high concentrations.  
3.2.4. Finding the optimal source and preparation of Aβ42 
Synthetic Aβ is notoriously difficult to work with, with difficulties in controlling the 
aggregations leading to reproducibility issues.217 Sources of synthetic Aβ can vary 
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greatly in their aggregation kinetics depending on the supplier, as well as between 
batches. In addition, there are numerous preparation protocols, which can greatly 
influence aggregation kinetics. It was therefore important to find a source of Aβ with 
reliable aggregation kinetics, that could reproducibly produce an inflammatory 
response. Three Aβ sources were characterised, following their manufacturer’s 
preparation instructions: 
 
Figure 15: Determining optimal batch of Aβ42 
Three different Aβ sources were tested: (i) AnaSpec dissolved in SSPE buffer, (ii) Bachem dissolved in 
NH4OH and (iii) Abcam dissolved in GuHCl. (a) Aβ concentrations measured with BCA assay to 
calculate stock concentration and to confirm the concentrations required for kinetics studies. Error bars 
represent the mean ± SD of three technical repeats. (b) Aβ measured with BCA was diluted 10-fold and 
kinetics were measured with ThT. Measurements were taken every 2 min. A 4-parameter fit has been 
applied to the data. Error bars represent the mean ± SD of three technical repeats. (c) BV2 cells were 
treated with early Aβ aggregates (2.5 μM) for 24 hr and TNFα levels were measured with an ELISA. 
The vehicle controls were SSPE, NH4OH, and GuHCl, respectively. Error bars represent the mean ± 
SD of three wells. (Unpaired two-tailed t-test: n = 3 for all. Vehicle vs AnaSpec: t4 = 2.537, p = 0.06; 
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Of the three Aβ sources tested, the batch from Abcam was the only one that produced 
a significant inflammatory response in BV2 cells (Figure 15c). The vehicle control did 
not produce a strong response, suggesting that the GuHCl itself was not responsible 
for this response. Moreover, aggregation kinetics were measured using ThT, a 
benzothiazole salt amyloidophilic dye that fluoresces when bound to beta-sheet 
structures.197 The kinetics of the Abcam batch were more consistent with the 
characteristic sigmoidal shape of Aβ aggregation, than the other two, and were 
reproducible when repeated. The 10 μM kinetics in the AnaSpec and Bachem batches 
did not have a visible lag phase, suggesting that they contained seeds, speeding up 
aggregation (Figure 15b). The Abcam Aβ was therefore used for future Aβ 
experiments due to its strong inflammatory response and consistent aggregation 
kinetics. 
It should be noted that a batch of the Bachem and Abcam Aβ42 were also prepared 
using HFIP treatment, as per the manufacturer’s instructions. However due to 
significant protein loss from the nitrogen stream drying step, the HFIP method was not 
used again. 
A large batch of Abcam Aβ was purchased, prepared in GuHCl, and passed through 
a column to ensure that there were no seeds in solution that could affect aggregation. 
Fast protein liquid chromatography (FPLC) was carried out by Dr. Patrick Flagmeier, 
as described previously.194 It was then re-characterised using SDS-PAGE, BCA, and 
ThT-based kinetics (Figure 16).  
 
Chapter 3: Preclinical Testing of Passive Immunotherapies 
47 
 
3.2.5. Abcam Aβ42 characterisation 
 
Figure 16: Abcam Aβ42 characterisation after FPLC 
Characterisation of Abcam synthetic Aβ42 using (a) SDS PAGE to determine the molecular weight and 
(b) BCA assay measurements (total protein concentration) of various dilutions of the Abcam Aβ sample, 
that were then diluted 10-fold for kinetics studies. Error bars represent the mean ± SD of three technical 
repeats. (c) Raw data of Aβ aggregation kinetics measured with ThT. Error bars represent mean ± SD 
of three technical repeats. (d) Normalised fluorescence intensity (with background subtraction), 
4-parameter fit has been applied to each data set. Error bars represent mean ± SD of three technical 
repeats. 
The molecular weight of the Abcam Aβ was confirmed to be around 4.5 kDa with SDS-
PAGE (Figure 16a). A BCA assay was used to measure the stock concentration of 
the protein (~100 μM), as well as two dilutions (50 μM and 20 μM) (Figure 16b). These 
concentrations were diluted 10-fold and their aggregation kinetics were measured 
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In order to reliably get monomers, early aggregates, or fibrils, three time points were 
selected and imaged (Figure 17). These time points were then used for future 
experiments. Aliquots of stock Aβ were flash-frozen and kept in -80 °C for future 




Figure 17: Aβ42 aggregation time points 
(a) Normalised ThT fluorescence intensity (with background subtraction and 4-parameter fit) of 10 μM 
synthetic Aβ42, showing the three time points that were chosen to represent Aβ42 (i) monomers, (ii) 
early aggregates, and (iii) fibrils. Points represent the mean from three wells; error bars not shown. 
(b) Representative ThT images of Aβ (i) monomers, (ii) early aggregates and (iii) fibrils using TIRF 
microscopy. Concentrations for imaging were 100 nM Aβ and 25 μM ThT. 
3.2.6. Aβ42 time and concentration optimisation for neuroinflammation assay 
Now that a source of Aβ had been characterised and shown to elicit a strong 
inflammatory response in BV2 cells, the time durations of future experiments needed 
to be optimised. BV2 cells were treated with a high concentration of Aβ42 (2.5 μM) to 
ensure a strong response, for up to 48 hours, with supernatant collected at 3, 6, 24, 
36, and 48-hour time points. TNFα levels in the supernatant were measured with a 
TNFα ELISA. 
i ii iii 
Monomers Early aggregates Fibrils 
a 
b 





Figure 18: Aβ42 optimisation 
BV2 cells, plated at 50,000 cells/well, were treated with 2.5 μM synthetic Aβ42 for 3, 6, 24, 36, and 
48 hr, without media changes.  Error bars represent the mean ± SD of three wells. (One-way ANOVA: 
F(9, 20) = 95.01, p < 0.001. Post hoc Tukey test: n = 3 for all: Vehicle (3 hr) vs Aβ42 (3 hr): 
p > 0.99; Vehicle (6 hr) vs Aβ42 (6 hr): p = 0.87; Vehicle (24 hr) vs Aβ42 (24 hr): p < 0.001; 
Vehicle (36 hr) vs Aβ42 (36 hr): p < 0.001; Vehicle (48 hr) vs Aβ42 (48 hr): p < 0.001. Aβ42 (24 hr) vs 
Aβ42 (36 hr): p > 0.99; Aβ42 (24 hr) vs Aβ42 (48 hr): p = 0.71; Aβ42 (36 hr) vs Aβ42 (48 hr): p = 0.22). 
There was no significant TNFα production in the first 6 hours. 24 hours was the first 
time point at which there was significant TNFα production, with no significant change 
at the 36 or 48-hour time points. This suggested that 24 hours was the optimal time of 
treatment with Aβ42 at 2.5 μM, to get a strong inflammatory response. It should be 
noted however, that 2.5 μM is much higher than the physiological levels of Aβ42. 
Lower concentrations of Aβ may require longer treatment before getting a significant 
inflammatory response. However, the inflammatory response of the vehicle control 
increased with time (Figure 18), especially after the 24-hour time point, most likely 
due to the cells not having any media changes. To reduce this non-Aβ mediated 
response, cell supernatants were collected and replaced with fresh media (including 
Aβ42) every 24 hours, in long-term experiments (lasting over 24 hours).  




Figure 19: BV2 response to low concentrations of Aβ aggregates 
Timecourse of BV2 cells treated with various concentrations of synthetic Aβ42 (Abcam), that was 
aggregated at 10 μM for 40 min at 37 °C in a microplate under quiescent conditions. Media was 
collected and changed every 24 hr. LPS concentration used was 10 ng/mL (not shown). Error bars 
represent the mean ± SD from three wells.  
High (micromolar) concentrations of Aβ42 can cause a strong TNFα response in BV2 
cells within 24 hours (Figure 18). However, when using lower and more physiological 
concentrations of Aβ42, the TNFα response took longer than 24 hours to be detected 
(Figure 19). The response was concentration-dependent, and interestingly also 
appeared to increase with time, suggesting a microglial sensitisation over time. The 
baseline signal also increased with time, most likely due to cell proliferation throughout 
the course of the experiment. However, aggregate-treated cells had a steeper 
increase in TNFα production, as has been previously reported in similar experiments 
with Aβ-treated BV2 cells.218  
Now that the neuroinflammation assay was optimised for use with synthetic Aβ42, it 
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3.3. Preclinical testing of MedImmune Aβ42 antibody (MedI ATB) 
MedImmune (now AstraZeneca) had a proprietary antibody that bound preferentially 
to Aβ42 than Aβ40, by binding to the C-terminus. This antibody had a mutation in the 
Fc domain so that it wouldn’t bind to Fc-receptors on phagocytes, reducing the 
possibility of the inflammatory response being mediated by stray microglia recognising 
the Fc domain. This antibody required further preclinical testing, which provided an 
opportunity to implement the newly optimised neuroinflammation assay.  
The concentration of the MedI ATB was measured using a BCA assay. 
 
Figure 20: Measuring MedI ATB concentration 
Serial dilution of MedImmune antibody concentrations measured using BCA assay. Neat antibody and 
1:25 dilution not shown as they exceeded the sensitivity range of the assay (2,000 μg/mL) and could 
not be detected. Error bars represent the mean ± SD of three technical repeats. 











To test the MedImmune antibody’s selectivity for Aβ42, an immunoprecipitation assay 
was carried out, following a previously reported protocol with a few adaptations.201 
 
Figure 21: Aβ42 immunoprecipitation with MedI ATB42 
(a) Schematic of immunoprecipitation assay. Magnetic beads covered in Proteins A & G were added to 
2 nM Aβ42. Proteins A & G are surface proteins found in the cell wall of bacteria, which bind to a wide 
range of immunoglobulins. They differ in their binding strength to antibodies from different species and 
subclasses. In this way, beads mimic fragment crystallisable (Fc) receptors found on effector cells, 
which normally bind to the Fc region of antibodies that are attached to infected cells or invading 
pathogens. In the case of this assay, binding to the Fc region of the antibody left the antigen-binding 
fragments (Fab) free to bind to their protein targets. The beads, and by extension the antibody and 
bound protein, could then be pulled down using a magnet. The free-roaming protein in the solution was 
then measured using an ELISA.  (b) Two concentrations of the MedI ATB were added to 2 nM Aβ42. 
Free Aβ in solution was measured using a human Aβ42 ELISA. Beads only control was magnetic beads 
without antibody. Isotype control was NIP228 at 20 nM. Error bars represent the mean ± SD of three 
independent experiments. (One-way ANOVA: F(3, 44) = 137.9, p < 0.001. Post hoc Dunnett test: Beads 
only vs 0.2 MedI ATB: p < 0.001; Beads only vs 20 MedI ATB: p < 0.001; Beads only vs Isotype control: 
p = 0.66). 
The MedI ATB was able to bind and significantly pull-down the Aβ42 in solution at 
0.2 nM and 20 nM (Figure 21b). To rule out non-specific binding, an isotype control 
antibody (NIP228) was used and did not significantly reduce the concentration of Aβ42 
in solution. This was further supported with a beads-only control (without antibody) 
that did not significantly reduce the free Aβ42 in solution. The Aβ42 samples used 
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3.3.2. Testing MedI ATB with neuroinflammation assay  
 
Figure 22: Neuroinflammation assay with MedImmune antibody 
(a) BV2 cells treated with MedI ATB and 2.5 μM Aβ42 simultaneously. TNFα concentration in cell 
supernatant was measured 24 hr after treatment with TNFα ELISA. Error bars represent the mean ± 
SD of three wells. (One-way ANOVA: F(6, 14) = 189.8, p < 0.001. Post hoc Tukey test: Fibrils vs 0 μM: 
p < 0.001; 0 μM vs 2.5 μM: p > 0.99; 0 μM vs 25 μM: p = 0.19; 2.5 μM vs 25 μM: p = 0.28). (b) BV2 
cells treated with pre-incubated MedI ATB and Aβ42; final concentration of Aβ42 was 2.5 μM. MedI 
ATB was added in various concentrations (as seen in graph) to 10 μM Aβ42 monomer solution for 15 
min at room temp under quiescent conditions before following standard aggregation protocol for 
producing aggregates (10 μM Aβ42, ~45 min at 37 °C in 96 well microplate under quiescent conditions). 
Final concentrations of MedI ATB were a 4-fold dilution of the values presented on the graph. TNFα 
concentration in cell supernatant was measured 24 hr after treatment with TNFα ELISA. Error bars 
represent the mean ± SD of three wells. (One-way ANOVA: F(5, 12) = 74.64, p < 0.001. Post hoc Tukey 
test: 0 μM vs 5 μM: p < 0.001; 0 μM vs 10 μM: p < 0.001). 
Early aggregates caused significantly higher TNFα production than fibrils             
(Figure 22a), suggesting that early aggregates are the more toxic species. 
Furthermore, adding the MedI ATB (at various concentrations) and the Aβ42 
aggregates simultaneously did not have a significant effect on TNFα levels compared 
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bind to the Aβ42 aggregates, which would have quickly started adopting a fibrillar form 
at 37°C. However, pre-incubation of MedI ATB (5 μM and 10 μM) with monomeric 
Aβ42 prior to aggregation, significantly reduced the levels of TNFα (Figure 22b). This 
suggested that the MedI ATB was able to bind to monomeric and early aggregate 
species, potentially affecting aggregation kinetics, but was not able to effectively bind 
to Aβ42 fibrils. To confirm whether the MedI ATB had an effect on aggregation kinetics, 





Figure 23: Aβ42 aggregation kinetics + MedI ATB 
Normalised ThT kinetics of 2 μM recombinant Aβ42, with various concentrations of MedI ATB. Each 
dot represents the mean of three technical repeats. Error bars not shown. 
An increase in MedI ATB concentration caused a delay in Aβ42 aggregation by 
increasing the length of the lag phase. This confirmed that the MedI ATB had an effect 
on aggregation kinetics and could explain the significantly reduced inflammatory 
response in cells treated with pre-incubated MedI ATB and Aβ42 monomer compared 
to those treated with Aβ42 aggregates alone (Figure 22b).  
Recombinant Aβ42 was used for this particular experiment instead of synthetic as it 
was carried out in conjunction with the liposome assay; an assay that had been 
previously optimised with recombinant Aβ42 by Dr Patrick Flagmeier and Dr 
Suman De.194  
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3.3.3. Liposome assay 
The liposome assay was carried out by Dr Patrick Flagmeier and Dr Suman De. 
The liposome assay measures a protein’s ability to permeate a lipid membrane. 
Seeing as the permeabilisation of cell membranes through non-specific binding is one 
of the toxic mechanisms of Aβ aggregates, we investigated whether the MedI ATB 
would be capable of preventing this permeabilisation.  
 
 
Figure 24: Liposome permeabilisation assay 
(a) Schematic of liposome permeabilisation assay carried out by Patrick and Suman. (b) Results from 
liposome permeabilisation assay, using 5 nM recombinant Aβ42 early aggregates (based on kinetics 
from Figure 23). MedI ATB concentrations for liposome assay: 0, 7.5, 75, 150, 750, 7500 ng/mL (0, 
0.05, 0.5, 1, 5, 50 nM). 9 fields of view were analysed for each condition. A 4-parameter fit has been 
applied to the data (red line). Error bars represent the mean ± SD from two independent experiments. 
The antibody reduced calcium influx in a concentration-dependent manner, due to the 
binding and prevention of Aβ42 aggregates from penetrating the liposomes. The half 
maximal inhibitory concentration (IC50) of the MedI ATB was 165.1 ng/mL. 
a 
b 
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3.4. Improvements to the neuroinflammation assay 
3.4.1. Primary cells 
In an effort to increase the neuroinflammation assay’s relevance to the actual disease 
condition, the BV2 immortalised cell line was substituted with primary rat astrocytes 
(cultured from 1-7 day old rat pups from the Department of Veterinary Medicine) and 
commercially available human primary astrocytes (ScienCell Research Laboratories, 
SC-1800) supplied by the Institute of Neurology at University College London. 
However, initial experiments at the Department of Chemistry had high basal levels of 
TNFα, suggesting endotoxin contamination, so experiments with primary cells were 
continued at AstraZeneca, which was better equipped for sensitive tissue culture 
experiments. At AstraZeneca, primary mouse microglial cells were cultured from 
mouse pups.  
As these cells were from a mixed glial prep, immunocytochemistry was used to ensure 
that most cells were microglial. 
 
Figure 25: Primary mouse microglia immunostaining 
Primary mouse microglia (50,000 cells/well) were immunostained with Hoechst (nuclear stain), Iba1 
(microglial stain), GFAP (astrocytic stain) and NeuN (neuronal stain).  
Immunostaining confirmed that the cells were mostly microglial. The inflammatory 
response of these cells was then tested using a Meso scale Delivery (MSD) multiplex 
ELISA. An MSD ELISA allows for the testing of several analytes simultaneously, using 
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proprietary plates that have several electrodes and corresponding linkers per well. 
This works similarly to a sandwich ELISA, except the secondary antibody is 
conjugated with a SULFO-TAG that can be read by an MSD proprietary plate reader. 
 
Figure 26: Inflammatory response from BV2 cells vs primary mouse microglia 
BV2 cells and primary mouse microglia were treated with 2.5 μM Abcam Aβ42 or 10 ng/mL LPS for 
24 hr. An MSD multiplexed ELISA was carried out on a panel of 7 cytokines/chemokines including IL-
1β, IL-6, RANTES, MCP-1, MIP-1α, MIP-1β, TNFα. Error bars are mean ± SD of three wells from one 
biological repeat.  
An MSD inflammatory panel was used as an exploratory means to better understand 
the signalling mechanisms involved in Aβ42-induced inflammation. RANTES, 
otherwise known as CCL5, is a pro-inflammatory chemokine heavily implicated in 
AD.219 The production of RANTES is TRIF-signalling dependent, so the increase in 
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signalling pathway of TLR4 activation (Figure 26). Surprisingly, there were quite a few 
differences between the responses of the two cell types, particularly concerning 
RANTES and MIP-1β. Perhaps a Luminex screen, a fluorescent bead-based 
immunoassay that allows for multiplex detection of up to 100 analytes simultaneously 
would have been a less biased approach as it would have scanned a larger number 
of inflammatory markers, however this was not available at the time. 
3.4.2. Imaging TNFα on the cell membrane 
The neuroinflammation assay described in this chapter allows for the bulk 
measurement of TNFα in the cell supernatant of stimulated microglial cells. While this 
provides useful information about the neuroinflammatory potential of the stimulants, 
this assay does not provide an indication of how many cells were activated, or to what 
extent. Moreover, this assay takes between 24 hours (for high concentrations of toxic 
aggregates) and 120 hours (for lower concentrations). By directly imaging TNFα on 
the membrane of these cells, we can directly quantify levels of TNFα per cell, at a 
much shorter time scale. TNFα is normally cleaved from the membrane by TACE, 
however this can be prevented by the addition of a metalloprotease inhibitor, such as 
TAPI-0 (Figure 27). 
 
Figure 27: TACE-inhibition 
mTNFα = membrane TNFα, sTNFα = soluble TNFα, TAPI-0 = TNFα protease inhibitor 
LPS-stimulation causes the trafficking of TNFα to the cell membrane where it is cleaved by TACE (or 
ADAM17). This cleavage can be inhibited by the metalloprotease inhibitor TAPI-0, preventing the 
release of soluble TNFα from the membrane. TNFα on the membrane can then be imaged using a 
fluorescent TNFα antibody. 
Cells were plated at a density of 100,000 cells/well in Ibidi treat 8-well imaging slides. 
At this density, there were enough cells that it was easy to locate them with a confocal 
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microscope, but not enough to cause cell clumping. Initial experiments using non-fixed 
cells had significant non-specific binding from the TNFα antibody.  
 
Figure 28: Non-specific binding from TNFα antibody 
Representative image of untreated cells labelled with TNFα antibody, taken on a fluorescence-lifetime 
imaging (FLIM) confocal microscope.  
Non-specific binding was reduced by fixing the cells with 2% PFA and blocking with a 
blocking solution (PBS with 0.5% v/v BSA, 4 μg/mL rat anti-mouse FcγRII/III, 5% v/v 
rabbit serum).  
Autofluorescence was detected at 488 nm in untreated cells without antibody, TAPI-0, 
or LPS (Figure 29). Since most cell autofluorescence is detected at shorter 
wavelengths, the anti-mouse Alexa Fluor (AF) 488 TNFα antibody was replaced with 
an AF 647 antibody. 
 
Figure 29: Cell autofluorescence at 488 nm 
Substantial autofluorescence was detected from BV2 cells at 488 nm.  
5 μm 
5 μm 
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Fixing and blocking the cells, as well as switching to the AF 647 antibody, greatly 
reduced non-specific binding and cell autofluorescence, resulting in cleaner images. 
An LPS dose-response was carried out to optimise LPS concentration and timescale 
of these experiments (Figure 30).  
 
Figure 30: LPS-dose response 
(a) Representative images of BV2 cells treated with various concentrations of LPS for 2 hr before being 
fixed and imaged using a confocal FLIM microscope. Reagent concentrations used were 1 μM TAPI-0 
and 10 μg/mL (66.7 nM) Alexa Fluor 647 anti-mouse TNFα antibody. (b) The same cells were then 
imaged with an epifluorescence microscope at a lower magnification to increase the number of cells 
per image. (c) The epifluorescence microscope images were analysed in ImageJ by applying a 
20 μm 20 μm 20 μm 20 μm 
Control LPS 1 ng/mL LPS 10 ng/mL LPS 50 ng/mL 
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threshold to the control image with the highest fluorescence intensity. This threshold was then applied 
to the LPS conditions and the number of localisations above the threshold were counted. Error bars 
represent the mean ± SD of 10 images. (One-way ANOVA: F(3, 28) = 17.41. p < 0.001. Post hoc 
Dunnett test: Control vs 1: p = 0.27; Control vs 10: p = 0.005; Control vs 50: p < 0.001). 
Cell autofluorescence and non-specific binding were greatly reduced, and clear bright 
fluorescent rings were detected in the confocal slices. Two hours of LPS treatment at 
10 or 50 ng/mL was sufficient for TNFα detection.  
3.5. Conclusions and future work 
In this chapter a neuroinflammation assay has been optimised to measure the TNFα 
release from Aβ42-treated BV2 cells. The conditions that required optimisation 
included the LPS concentration used as a positive control, the FBS source and 
concentration, the post-experimental handling of cell supernatant (prior to analysis), 
as well as the source of Aβ42, its concentration and time course for inflammation. This 
assay has the sensitivity to detect down to picomolar concentrations of Aβ42      
(Figure 19). The optimisation of this assay using synthetic Aβ42 was crucial before 
moving on to more clinically relevant human biofluid samples, of which only low 
volumes are available. The development of this assay for the analysis of human AD 
soluble aggregates will be covered in Chapter 4. In future experiments, the 
conventional one-target ELISA can be substituted with a multiplex ELISA to measure 
levels of multiple cytokines and chemokines simultaneously.  
The current neuroinflammation assay has a few limitations, namely that there is an 
increase in baseline signal over time, and that the TNFα ELISA experiments are very 
time-intensive (Figure 19). An alternative neuroinflammation assay has been 
proposed to address these limitations, that uses fluorescence imaging of TNFα directly 
on the cell membrane. Future experiments could combine this TNFα imaging method 
with an ImageStream® Flow Cytometer to get more quantitative and higher-throughput 
measurements, by sorting cells based on fluorescence (TNFα release). The cells 
could be treated with synthetic Aβ and brain-derived soluble aggregates to assess 
their agonism on the pathway. Alternatively, instead of using a flow cytometer, 
unlabelled TNFα antibodies could be coupled with a non-toxic dye (e.g. Incucyte® 
Fabfluor-488 antibody labeling dyes) and the cells could be imaged live using an 
Incucyte® live-cell imaging system. Another idea would be to stain Aβ42 aggregates 
with a pH-sensitive fluorophore (e.g. Incucyte® pHrodo® Red Cell Labeling Kit for 
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Phagocytosis) and assess microglial phagocytosis of Aβ42, similarly to what has been 
reported previously.220 Furthermore, instead of using BV2 immortalised cells for these 
experiments, switching to primary mouse microglia would make the assay a more 
relevant model of neuroinflammation. However, microglial genes are not very well 
conserved between mice and humans, resulting in large biochemical and 
pharmacological differences. Some examples include TLR, FCγ, and SIGLEC 
receptors which are highly expressed in human but not mouse microglia, different 
expression of several transcription factors, disparities in cell proliferation and NO 
production, varied responses to species-specific cell surface antigen presentation 
proteins, and opposite responses to certain drugs such as valproic acid and 
propentofylline.221–223 There is also limited overlap of microglial genes regulated during 
ageing, suggesting a difference in the way mouse and human microglia age.222 For 
these reasons, using primary human microglia or iPSC-derived microglia would be 
more clinically relevant as they would better reflect the human condition. 
A proprietary anti-Aβ42 MedImmune antibody, that binds to the C-terminus of the 
Aβ42 peptide, has been tested using a variety of assays to measure its effects on the 
inflammatory response, liposome permeability, and its binding efficiency. The 
immunoprecipitation experiment in conjunction with the neuroinflammation 
experiments, suggested that the antibody has a high affinity for monomeric and early 
aggregated species of Aβ42, and a potentially lower affinity for Aβ42 fibrils. This was 
seen through the reduction of TNFα production when the antibody was pre-incubated 
with monomeric Aβ42, slowing down aggregation kinetics (Figure 23), but not having 
an effect when added simultaneously with Aβ42 aggregates to the cells (Figure 22d), 
which would have quickly adopted fibrillar structures at 37°C, suggesting that the 
epitope is hidden in the fibrillar aggregates. This is supported by a conformational 
analysis of the Aβ42 peptide, suggesting that the C-terminus may be embedded in the 
core of Aβ fibrils.224 Another explanation could be that the antibody is ineffective due 
to the length of the aggregates, which require complete coverage by antibodies in 
order to block the inflammatory response. This explanation is unlikely however as the 
antibody was added at a concentration 1000-fold higher than the IC50 (165.1 ng/mL, 
~1.1 nM) determined using the liposome assay. The liposome assay also showed that 
the antibody can reduce calcium influx caused by Aβ42-mediated liposome 
permeabilisation in a concentration-dependent manner (Figure 24).  
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Seeing as the antibody can bind to monomeric and early aggregate species of Aβ42 
and slow down aggregation, this antibody could potentially be administered as a 
preventative drug to patients with mild cognitive impairment and therefore at risk of 
developing AD, or early AD patients before symptom onset. Early administration could 
potentially slow the aggregation of inflammatory Aβ42 aggregates by blocking the C-
terminus, which may play an important role in the structural stability and assembly of 
Aβ42.225 This antibody would most likely not be very effective in patients with more 
advanced AD, as the antibody does not effectively bind Aβ42 fibrils, or reduce 
aggregate-induced inflammation. Total Aβx-42 concentration, without denaturation, in 
homogenised AD brain is in the high picomolar - low nanomolar regime, and soluble 
Aβx-42 is found in low-high picomolar concentrations.178 The IC50 of the MedImmune 
antibody was calculated to be just over 1 nM using a physiologically relevant 
concentration of Aβ42 (5 nM). In order to achieve complete inhibition, the antibody 
would need to be in the brain at a concentration over ~6.6 nM (1 μg/mL), according to 
the 4-parameter fit (Figure 24) and would have to be administered at 1000-fold 
concentration as antibody concentrations in the brain are generally around a thousand 
times lower than in the blood, due to poor BBB permeability. Exact antibody 
concentrations would depend on pharmacokinetic studies on animals, the body 
clearance of the drug, and the individual weights of the patients.  
The neuroinflammation, liposome-permeabilisation, and immunoprecipitation assays, 
as described in this chapter are now set up for the preclinical testing of more passive 

















































4: Characterisation of Soluble Aggregates from AD Brain 
Parts of this chapter have been adapted from the following soon-to-be published manuscript: 
Dimitrios I. Sideris, John S. H. Danial, Derya Emin et al. Soluble amyloid beta-containing aggregates 
are present throughout the brain at early stages of Alzheimer’s disease (accepted in Brain 
Communications, May 2021). 
The liposome assay was carried out by Dr Suman De and Zengjie Xia; AD PAINT was carried out by 
Dr John Danial and Dr Jason C. Sang; AFM was carried out by Dr Francesco Simone Ruggeri; SiMPull 
was carried out by Derya Emin, Yu P. Zhang, and Dr Evgenia Lobanova. 
4.1. Introduction 
Protein aggregation likely plays a key role in the initiation and spreading of Alzheimer’s 
disease through the brain. Soluble aggregates of Aβ are believed to play a key role in 
this process. However, the aggregates present in humans are still poorly characterised 
due to a lack of suitable methods required for characterising the low concentration of 
heterogeneous aggregates present. A variety of sensitive biophysical methods have 
been employed to characterise the aggregates present in human AD brains at 
Braak stage III.  
AD has a typical pathological progression, starting in the hippocampal/entorhinal 
cortex regions and spreading to the temporal, parietal, and frontal lobes before 
affecting the occipital lobe.18,226 For our initial experiments we decided to study the 
soluble aggregates from Braak stage III brain tissue, which is at the early stages of 
disease and therefore before the appearance of global pathology, to assess regional 
variability within the same patient and between patients.16,227 After establishing that 
our assays have sufficient sensitivity to detect the aggregates present, we 
characterised the soluble aggregates from eight brain regions from three Alzheimer’s 
disease patients. Two distinct regions were then chosen to compare in more detail, 
the hippocampus (HPC), which is significantly affected early in the disease, and the 
visual association cortex (VAC), a region affected later in the disease, with the latter 
acting as an internal control for each brain. The similarities and differences between 
the soluble aggregates in these regions have been identified by characterising their 
size, structure, neurotoxicity, inflammatory potential, and capability to permeabilise a 
lipid membrane. 




4.2. Overview of assays used to characterise soluble aggregates 
 
 
Figure 31: Overview of assays used in this chapter to characterise soluble aggregates 
aCSF = artificial cerebrospinal fluid, TIRF = total internal reflection fluorescence 
(a) Extraction of soluble aggregates from human brain tissue through soaking in aCSF. 
(b) Neuroinflammation assay using BV2 cells to measure production of TNFα. (c) Liposome assay used 








measure neurotoxicity. (e) Single-molecule pull-down imaging used for the characterisation of Aβ-
containing aggregates. (f) Aptamer DNA-PAINT imaging used to characterise the size and number of 
aggregates. (g) AFM imaging of 3-D morphology used to characterise morphology and cross-sectional 
dimensions of the aggregates. 
4.3. Optimisation of brain soaking prep 
Initially, with the help of our lab technician Helen Dakin at the Dementia Research 
Institute (DRI) in Addenbrooke’s hospital, we reproduced the extraction process of 
soluble aggregates from soaking brain tissue as previously described (Figure 32).178  
 
Figure 32: Initial brain soaking prep as previously reported178 
Brain tissue is chopped, mixed, and weighed before being soaked in aCSF buffer. The soluble 
aggregates are extracted from the brain tissue after several centrifugation steps, including an 
ultracentrifugation step, and a 72-hr dialysis.  
There were a few steps in the protocol that could be improved for reproducibility and 
convenience of future preps. A standardised weight of 300 mg was chosen for the 
brain tissues going forward, to reduce variability between preps. To assess intra- 
tissue variability, three different cuts of the same brain tissue were passed through the 
prep and the amount of soluble protein produced was measured (Figure 33a).  
Furthermore, access to an ultracentrifuge was limited, so the necessity of 
ultracentrifugation of these samples was assessed by comparing ultracentrifugation 
and benchtop centrifugation (Figure 33b). Moreover, the 72-hour dialysis step 
increased the length of the brain soaking prep by 3 days, so its necessity was also 
assessed by comparing dialysed and undialysed samples (Figure 33c). 





Figure 33: Optimisation of brain soaking protocol 
(a) Frontal cortex brain tissue from patient AD2 was cut into three 300 mg pieces. The soluble proteins 
were extracted from these pieces through soaking, and their total protein content was measured with a 
BCA assay. Error bars represent the mean ± SD of three wells. (One-way ANOVA: F(2, 3) = 2.663. 
Post hoc Tukey test: Cut 1 vs Cut 2: p = 0.2111; Cut 1 vs Cut 3: p = 0.3636; Cut 2 vs Cut 3: p = 0.8251).  
(b) BV2 cells were treated for 96 hr with brain-derived soluble aggregates prepared either with 
ultracentrifugation or benchtop centrifugation. TNFα responses were measured by ELISA. Error bars 
represent the mean ± SD of three wells. (One-way ANOVA: F(3, 8) = 2.069, p = 0.18. Post hoc Tukey 
test: Control-A vs Control-B: p = 0.68; AD-A vs AD-B: p = 0.95). (c) BV2 cells were treated for 96 hr 
with soluble aggregates prepared with or without a dialysis step.  TNFα responses were measured by 
ELISA. Error bars represent the mean ± SD of three wells. (One-way ANOVA: F(2, 6) = 23, p = 0.001. 
Post hoc Tukey test: Vehicle vs Dialysed: p = 0.001; Vehicle vs Undialysed: p = 0.26; Dialysed vs 



























The three different cuts from the same piece of brain tissue did not have significant 
variability in their total soluble protein content (Figure 33a). For this reason, it was 
assumed that there wasn’t significant intra-tissue variability for any of the regions. 
Centrifugation was used to remove cell debris. The type of centrifugation did not 
appear to influence the inflammatory potential of the soluble aggregates (Figure 33b). 
For this reason, the ultracentrifugation step was replaced with benchtop centrifugation 
at 14,000 g(av). 
Dialysis was used to remove any small molecules from the samples that might affect 
our assays, such as excitatory amino acids and other DAMPs. Dialysed samples were 
significantly more inflammatory than undialysed samples (Figure 33c), possibly due 
to unremoved anti-inflammatory agents in the undialysed samples. This suggested 
that this step was critical and was therefore kept for future preps. 
4.3.1. Non-AD controls 
To identify whether the soluble aggregate-induced inflammation is AD-specific, 
comparisons should be made with negative (non-AD) control brain. However, finding 
suitable negative control brain is very challenging, as it requires finding age-matched 
controls who have not passed away from brain/spinal cord injuries/illnesses that might 
affect brain cell machinery and also have no AD pathology or cognitive impairment. 
This is complicated further by the fact that non-demented elderly individuals often 
present substantial plaques and tangles without cognitive issues.228–231 It is also 
important to note that the AD brains analysed in this study were from Braak stage III 
(early disease) and are therefore not likely to display big differences to age-matched 
non-demented brains that will also have pathology. This was confirmed by treating 
BV2 cells with soluble aggregates extracted from our three AD brains, and from one 
age-matched control brain, for 96 hours. 





Figure 34: AD brain vs control 
(a)  BV2 cells were treated with frontal cortex-derived soluble aggregates from three AD patients and 
one non-AD control. TNFα in cell supernatant was measured by ELISA. Error bars represent the mean 
± SD of three wells. (b)  Live and dead cells from the neuroinflammation experiment were counted with 
Trypan Blue staining. Error bars represent the mean ± SD of three wells.   
As expected, great variability was observed in the neuroinflammatory response  when 
comparing between patients and there was no clear difference between AD vs control 
brain (Figure 34a). There also does not appear to be a difference between AD vs 
control in the live cell counts (Figure 34b). It should be noted that the control patient’s 
cause of death was due to a malignant tumour in the spinal cord, and had 
neurofibrillary tangle pathology (Table 2), further highlighting the difficulty in obtaining 
suitable control brain. Studies focusing on later stages of disease progression (e.g. 
Braak stage VI), would benefit more from a comparison with age-matched control brain 
than early disease studies. Due to the complexity of finding suitable negative control 
brain, and our focus being on the early stages of the disease, negative control brains 












































4.3.2. Brain survey 
With an optimised brain soaking prep, eight different brain regions from three AD 
patients were analysed (Figure 35a). These regions spanned areas that are typically 
affected early in disease, and regions that are affected later in disease. 
 
Figure 35: AD brain regions analysed 
FC = frontal cortex, EC = entorhinal cortex, PVC = primary visual cortex, VAC = visual association 
cortex, PP = posterior parahippocampal gyrus, HPC = hippocampus, AC = anterior cingulate cortex, 
CBL = cerebellum 
(a) Diagram of the 8 regions that were removed, soaked, and used for experimentation, from three AD 
patients (Braak stage III). Total protein concentrations of these regions were measured with BCA and 
presented as (b) regional variability, where each bar represents a different patient (AD1, AD2, AD3), or 
(c) patient variability, where each bar represents a different brain region. Error bars represent the 
mean ± SD of three technical repeats.  
Great variability was observed in the total protein concentrations of the soluble 
aggregate samples when comparing region-to-region (Figure 35b) or patient-to-
patient (Figure 35c). For this reason, the soluble aggregate samples were normalised 









4.4. Neuroinflammation assay with soluble aggregates 
BV2 cells were treated with the soluble aggregates derived from eight different regions 
from three AD patients to assess their inflammatory potential.  
 
Figure 36: Initial neuroinflammation brain survey 
FC = frontal cortex, EC = entorhinal cortex, PVC = primary visual cortex, VAC = visual association 
cortex, PP = posterior parahippocampal gyrus, HPC = hippocampus, AC = anterior cingulate cortex, 
CBL = cerebellum 
The 120 hr timepoint of BV2 cells treated with a 1:5 dilution of soluble aggregate samples from eight 
brain regions from (a) AD1, (b) AD2 and (c) AD3. (d) The average values from the three AD patients. 
TNFα in the cell supernatant was measured by ELISA. Vehicle control was aCSF at the same dilution 
as soluble aggregate samples. Error bars represent the mean ± SD from three wells.  
The samples from all three AD patients produced similar levels of TNFα and were all 
higher than the vehicle control (Figure 36a-c). The hippocampal samples appeared 
to be the most inflammatory overall (Figure 36d). However, the responses were not 
very strong making it difficult to identify differences between the different regions. To 










4.4.1. Cell density optimisation 
48-well microplates have a working volume of 300 μL. To reduce the volume of sample 
required for this assay, the 48-well microplates were replaced with 96-well microplates, 
with a working volume of 150 μL. This change was crucial for the use of precious 
clinical samples, where only small volumes were available. 96-well microplates have 
been used for similar TNFα studies, where BV2 cells were treated with toxic 
aggregates.216,232 To determine the optimal density of cells that would provide the 
strongest response, while maintaining low basal TNFα levels for the vehicle control, 
cells were plated at various densities and treated with soluble aggregates.  
 
Figure 37: Cell density optimisation 
BV2 cells were plated in 96-well microplates in three densities, (a) 25,000 cells/well, (b) 50,000 
cells/well and (c) 100,000 cells/well. They were treated with AD hippocampus-derived soluble 
aggregates at a 1:5 dilution (from patient AD1). Vehicle control was aCSF at 1:5 dilution. Error bars 
represent the mean ± SD from three wells.  
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Due to the low concentrations of these soluble aggregate samples, it took longer than 
24 hours for a detectable inflammatory response to occur. The vehicle control TNFα 
levels tended to increase with time, as the cells became more confluent. Cells plated 
at lower densities had the least stressed vehicle control wells, without compromising 
the soluble aggregate-derived inflammatory response, thus giving the cleanest signal. 
In Figure 37a, at the 96-hour time point there was a 5.6-fold difference between the 
vehicle control and the soluble aggregate-treated cells, and a smaller 4.8-fold 
difference at the 120-hour time point. Shortening the length of these experiments also 
reduced the sample volume required for each experiment, as media (containing 
soluble aggregates) was replaced every 24 hours. For these reasons, 96 hours was 
chosen as the optimal treatment time for future soluble aggregate experiments, with a 













4.4.2. Global inflammation in the brain of Braak stage III patients 
 
 
Figure 38: Brain survey neuroinflammation and cytotoxicity 
FC = frontal cortex, EC = entorhinal cortex, PVC = primary visual cortex, VAC = visual association 
cortex, PP = posterior parahippocampal gyrus, HPC = hippocampus, AC = anterior cingulate cortex, 
CBL = cerebellum. 
TNFα response from BV2 cells treated with soluble aggregate samples (diluted 1:5) from eight different 
brain regions, from three patients (a) AD1, (b) AD2, (c) AD3. Error bars are mean ± SD from three wells. 
(d) The TNFα response averaged by region; each point represents an average from three different 
Alzheimer’s disease patients. Vehicle control was aCSF at equal volume to soluble aggregate samples. 
LPS at 10 ng/mL was used as a positive control (not shown). Connecting lines have been added for 
visual clarity. Error bars are mean ± SD. (e) TNFα measurements from the 96-hr time point of the 
neuroinflammation assay. Each point represents one of the three Alzheimer’s disease patients. Error 
bars are mean ± SD. Statistical analysis has been carried out relative to the Vehicle control (One-way 
ANOVA: F(8, 18) = 5.989, p < 0.001. Post hoc Dunnett test against Vehicle: HPC: p < 0.001; CBL: 



































(f) Cell viability was assessed from cell supernatant from the 96-hr time point of the neuroinflammation 
assay using an LDH assay. Each point represents one of three Alzheimer’s disease patients. Data set 
has been normalised to lysed cells (100%) and the supernatant from the vehicle control on day 0 (0%). 
Error bars are mean ± SD.  
Samples from all eight regions appeared to be inflammatory and cytotoxic to varying 
degrees (Figure 38). This suggested that there was global pathology even at Braak 
stage III. Despite patient-to-patient variability, hippocampal aggregates appeared to 
be the most (or second most) toxic in all three patients (also seen in Figure 36). 
Going forward, two regions were chosen and analysed in more detail. These regions 
were the hippocampus, which is affected early in disease, and the visual association 
cortex, which is generally affected later in AD progression, and therefore served as an 
internal control for each brain. Interestingly, there is a subset of AD patients who have 
posterior cortical atrophy, with the visual cortex being the primary site of amyloid 
pathology,233 however it was confirmed by the neuropathologist at the Cambridge 
Brain Bank, that this was not the case for the patients in this study. 
Surprisingly, the soluble aggregates from the entorhinal cortex, an area with strong 
pathology, were not very inflammatory, and aggregates from the cerebellum, a region 
that does not develop mature neuritic amyloid plaques, only diffuse plaques in about 
half of AD patients,234 were very inflammatory. 
The frozen supernatant from the previous 96-hour neuroinflammation experiment 
(Figure 38d) was further analysed using an MSD multiplexed ELISA inflammatory 
panel (Figure 39). Due to space limitations on the 96-well MSD plate, and the cost of 









Figure 39: Survey of inflammatory markers 
Frozen supernatant from BV2 cells treated with 1:5 HPC and VAC aggregates for 96 hr were analysed 
using an MSD multiplexed ELISA inflammatory panel. Error bars are mean ± SD from two wells.  
Before carrying out the MSD experiment, the supernatant had been freeze-thawed 
twice; once for carrying out the TNFα brain survey, and once for carrying out the LDH 
assay. This might have caused the breakdown of certain cytokines and chemokines, 
especially IL-1β and IL-6, which do not appear to have caused a proper response, 
compared to Figure 26. It should also be noted that MIP-1α and MIP-1β responses 

























4.4.3. Neuroinflammation assay with primary mouse microglia 
HPC and VAC samples from patient AD1 were added to primary mouse microglia 
(same batch of cells as Figure 25), and the inflammatory response was measured 
using a TNFα ELISA. 




















Figure 40: Primary mouse microglia inflammatory response to soluble aggregates 
Primary mouse microglia were plated at 50,000 cells/well for 2 days prior to a 96-hr treatment with HPC 
and VAC (from patient AD1) at a 1:5 dilution. Vehicle control was aCSF buffer at a 1:5 dilution. LPS 
concentration was 10 ng/mL (not shown). Error bars represent mean ± SD from three wells. 
BV2 cells treated with HPC and VAC soluble aggregates (from patient AD1) produced 
a strong inflammatory response (Figure 40). Unfortunately, this experiment could not 
be repeated with samples from the other two patients due to COVID-19 limited access 











These cells were also treated with CellEvent Senescence Green Probe, a stain for β-
galactosidase, to measure cell senescence. Microglial cell senescence has been 
reported to play an important role in AD pathology.53,235 Cells that undergo senescence 
are irreversibly arrested at the G1 phase of the cell cycle, however they remain 
metabolically active. In the case of AD, microglial senescence may impair neuron-
sustaining functions and lead to the continuous release of pro-inflammatory cytokines 
and chemokines.235  
 
Figure 41: Cell senescence 
Primary mouse microglia were plated at 50,000 cells/well for 2 days prior to a 96-hr treatment with HPC 
and VAC soluble aggregates (from patient AD1) at a 1:5 dilution. Vehicle control was aCSF buffer at a 
1:5 dilution. 
Treatment with soluble aggregates from HPC and VAC did not appear to cause cell 
senescence (Figure 41). Interestingly, LPS treatment also did not result in cell 
senescence, contrary to what has been shown previously with several cell types of 
macrophages.236–238 Perhaps an anti-cancer drug (i.e. palbociclib) would be a more 
appropriate positive control for senescence,239,240 however due to COVID-19, access 








4.5. Soluble aggregates are liposome-permeable 
This work was carried out by Dr Suman De and Zengjie Xia. 
 
Figure 42: Liposome permeability 
(a) Ca2+ influx of each patient and region measured by liposome assay. Error bars are mean ± SD of 9 
fields of view. HPC and VAC samples have been repeated in an independent experiment and show a 
similar trend. (b) Ca2+ influx from two repeat experiments, averaged by brain region (HPC and VAC). 
Each point represents one of three Alzheimer’s patients. Error bars are mean ± SD. (HPC vs VAC: n = 
3, p = 0.007, t4 = 5.201).  
All brain regions from the three AD patients caused varying amounts of Ca2+ influx 
(Figure 42a), a measure of liposome permeability. The HPC samples caused 
significantly higher Ca2+ influx than the VAC samples (Figure 42b), suggesting that  
the HPC aggregates have a property that might make them more liposome- 
permeable. 
4.6. TLR4-mediation of inflammatory response 
TLR4 is the receptor most strongly associated with the production of TNFα and plays 
a central role in AD pathology by regulating neuroinflammation. To determine whether 
the soluble aggregate-induced TNFα response is mediated through TLR4, TLR4 
inhibitors TAK242 and RSLA were tested. TAK242, otherwise known as Cli-095, is a 
small molecule inhibitor that binds to the intracellular domain of TLR4, specifically the 
Cys747 residue, preventing TLR4 interaction with adaptor molecules TIRAP and 
TRAM. RSLA, lipid A from Rhodobacter sphaeroides bacteria, is a potent inhibitor of 
LPS and therefore TLR4 signalling. Prior to using soluble aggregates, the inhibitors 




















Figure 43: TLR4 inhibitors 
BV2 cells plated at 50,000 cells/well were treated with LPS and 1 μM TAK or RSLA for 24 hr. Vehicle 
was DMSO in distilled water at same dilution as inhibitors. LPS concentration was 10 ng/mL. TNFα in 
cell supernatant was measured by ELISA. Error bars represent the mean ± SD from three wells. (One-
way ANOVA for Vehicle, TAK, RSLA: F(2, 6) = 1.413, p = 0.31. One-way ANOVA for LPS, TAK+LPS, 
RSLA+LPS: F(2, 6) = 0.2522, p = 0.78). 
Both TLR4 inhibitors did not reduce the TNFα response from LPS-treated BV2 cells 
(Figure 43). To ensure that the inhibitor concentrations and incubation times were 
sufficient to get a response, this experiment was repeated with a higher concentration 
of TAK242 and was also incubated for 4-5 hours prior to the addition of LPS. 
 
 
Figure 44: TAK242 longer incubation 
BV2 cells plated at 25,000 cells/well were pre-treated with 1 μM (pink) or 3 μM TAK242 for 4-5 hr. 
Vehicle was DMSO in distilled water at same dilution as TAK242. LPS concentration was 10 ng/mL. 
Error bars represent the mean ± SD from three wells. (One-way ANOVA: F(3, 8) = 64.08, p < 0.001. 
Post hoc Dunnett test: LPS vs LPS 1 μM TAK: p < 0.001; LPS vs LPS 3 μM TAK: p < 0.001; LPS vs 






























Pre-incubation for 4-5 hours with the inhibitor caused a significant decrease in LPS-
induced TNFα production (Figure 44). Increasing the concentration to 3 μM but not 
including a pre-incubation step did not reduce the inflammatory response, suggesting 
that the pre-incubation step is critical for these experiments. 
TLR4 inhibitors are commonly used for short experiments, usually around 24 hours. 
However, the soluble aggregates require at least 96 hours before seeing a response. 
For this reason, a longer LPS experiment was carried out to determine whether 
TAK242 can block the inflammatory response in longer experiments.  
 
Figure 45: TAK242 long-term inhibition 
BV2 cells treated with LPS for 96 hr. Supernatant was collected every 24 hr, cells were washed with 
PBS, and pre-incubated with 1 μM TAK242 for 5 hr prior to LPS treatment. LPS concentration was 10 
ng/mL. Error bars represent mean ± SD from three wells. 
TAK242 inhibition was only able to block TNFα production for the first 48 hours  
(Figure 45), suggesting that TAK242 is better suited to shorter experiments. For this 
reason, TAK242 was not used for future soluble aggregate experiments. 
As the TAK242 was not effective at reducing TNFα levels in long-term experiments, a 
different method for testing TLR4-mediation was explored. TLR4 knockout 
immortalised bone-marrow derived macrophages (iBMMs) and wildtype iBMMs, 
obtained from Prof. Clare Bryant’s group at the Department of Veterinary Medicine, 
were treated with soluble aggregates. 





Figure 46: TLR4-mediation 
WT = wildtype, iBMMs = immortalised bone marrow-derived macrophages, TLR4-/- = TLR4 knockout, 
VAC = visual association cortex, HPC = hippocampus 
TNFα response from (a) wildtype and (b) TLR4-/- iBMMs treated with 1:5 dilution HPC and VAC soluble 
aggregates. The samples used were from patient AD3. The vehicle control was aCSF at 1:5 dilution. 
Error bars are mean ± SD from three wells. 
Wildtype iBMMs treated with VAC or HPC samples elicited a significant TNFα 
response, whereas the TLR4 knockout cells did not (Figure 46a), suggesting that this 













4.7. Aβ-containing fragments are likely driving the inflammatory 
response 
The solutions extracted from brain tissue are heterogenous mixtures of proteins. Aβ 
has been previously shown to be the major toxic species.178  For this reason, Aβ-
containing fragments, as well as Aβ42 specifically, were attempted to be quantified.  
 
 
Figure 47: Measuring concentration of Aβ in soluble aggregate samples 
(a) Western blot using 6E10 primary antibody and Licor Donkey anti-Mouse 800 secondary to detect 
APP fragments in soluble aggregate samples. 100 μg Abcam synthetic Aβ42 was used as a positive 
control. (b) Aβ42 ELISA used to measure concentration of Aβ42 in the soluble aggregate samples. 
Abcam synthetic Aβ42 was used as a positive control.  
Unfortunately, the levels of Aβ-containing fragments in the soluble aggregate samples 
were too low to detect using western blot (Figure 47a). Due to a dilution error, the 
synthetic Aβ42 used as a positive control was around 5x greater than the working 
concentration, resulting in a smear on the gel. This was not repeated due to sample 
limitations. Aβ42 concentration was also undetectable by ELISA (Figure 47b), 
suggesting that the concentration of Aβ42 in these samples is lower than the sensitivity 










One method for testing whether Aβ-containing aggregates were responsible for the 
inflammatory response, was to immunodeplete them from the soluble aggregate 
samples. Before this experiment, the widely used antibodies 6E10 (binds to Aβ-
containing fragments, amino acid residue 1-16) and 4G8 (binds to Aβ amino acid 
residues 17-24) were tested for their efficiency of binding to synthetic Aβ42. Isotype 
control antibodies were used to rule-out non-specific binding. 
 
Figure 48: Immunoprecipitation of synthetic Aβ42 
(a) Immunoprecipitation of monomeric synthetic Aβ42 (Abcam) by 6E10 and 4G8 antibodies. 
Concentration of each antibody was 20 μg/mL. Aβ42 was measured by a human Aβ42 ELISA. Error 
bars represent the mean ± SD of three technical repeats. (Unpaired two-tailed t-test, 6E10 vs MG1-45: 
n = 3, t4 = 31.56, p < 0.001; 4G8 vs A15126D: n = 3, t4 = 18.26, p < 0.001). 
Both 6E10 and 4G8 antibodies significantly pulled down Aβ42 monomer, to a similar 
degree. Both antibodies are widely used in literature for similar purposes, however 
6E10 was ultimately chosen as 4G8 has been shown to also react with the 
conformational epitope of non-Aβ aggregated fibrils (including α-synuclein).241 HPC 
and VAC samples from the three patients were immunoprecipitated with 6E10, and 
BV2 cells were then treated with soluble aggregates with and without 
immunoprecipitation. 
a b 





Figure 49: Immunodepletion of Aβ-containing fragments 
(a) TNFα response measured from BV2 cells treated with 1:5 diluted soluble aggregate samples that 
have either undergone (red) or not undergone (blue) immunoprecipitation using a 6E10 antibody. Each 
point represents an average from three patients. Vehicle control was aCSF at equal volume to soluble 
aggregate samples. LPS at 10 ng/mL was used as positive control (not shown). Error bars are mean ± 
SD. (b) TNFα measured at the 96-hr time point. Each point represents one of three Alzheimer’s disease 
patients. Error bars are mean ± SD. (Unpaired two-tailed t-test, HPC vs HPC + 6E10: n = 3, p = 0.04, 
t4 = 3.061; VAC vs VAC + 6E10: n = 3, p = 0.002, t4 =7.658). 
Samples immunodepleted of Aβ-containing fragments using the 6E10 antibody 
caused a significantly lower inflammatory response than samples that did not undergo 
immunodepletion for both HPC and VAC (Figure 49b). This data is consistent with 
Aβ-containing fragments playing a role in the soluble aggregate-mediated 
inflammatory response. To rule out non-specific binding, this experiment was repeated 
using an isotype control antibody (MG1-45). Only one sample was used from one 
patient due to limited availability of samples. 
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Figure 50: Immunoprecipitation using isotype control antibody 
TNFα response at the 96-hr time point, measured from BV2 cells treated with soluble aggregate 
samples at a 1:5 dilution, that have either undergone a pull-down using a 6E10 antibody (red) or isotype 
control (purple). Vehicle control was aCSF at equal volume to soluble aggregate samples. LPS at 10 
ng/mL was used as positive control (not shown). Error bars are mean ± SD from three wells. (One-Way 
ANOVA; F(2, 6) = 385.8, p < 0.001. Post hoc Tukey test: HPC vs HPC 6E10: n = 3, p < 0.001; HPC 
MG1-45 vs HPC 6E10: n = 3, p < 0.001; HPC vs HPC MG1-45: n = 3, p = 0.07). 
The HPC sample that was immunoprecipitated using 6E10 caused a significantly lower 
TNFα response to the non-immunoprecipitated HPC sample (Figure 50). 
Furthermore, the MG1-45 isotype control antibody did not affect the TNFα response, 
suggesting that the observed effects are not due to non-specific binding, but most 











4.8. Neurite retraction assay 
AD brain-derived Aβ has been shown to disrupt the microtubule cytoskeleton of 
primary rat hippocampal neurons, causing time-dependent neuritic degeneration.181 A 
live-cell imaging assay was optimised to measure the neurite retraction of primary 
mouse hippocampal neurons, similar to what has been done with human neurons.242 
4.8.1. Red lentivirus (synapsin promoter) 
Primary mouse hippocampal neurons, harvested by Robyn McAdam, were used for 
the optimisation of this assay. As primary cell preps rarely result in complete single-
cultures, it was important to distinguish whether the processes imaged with the 
IncuCyte® live-cell imaging technology, were neuronal or glial. For this reason, the 
cells were transduced with Neurolight Red Lentivirus Reagent, a lentiviral-based 
vector encoded with a red fluorescent protein (mKate2) driven off a synapsin promoter, 
according to the manufacturer’s instructions. They were then imaged using the 
IncuCyte® at 20x magnification.  
 
Figure 51: Red lentivirus 
Primary mouse hippocampal neurons plated at a density of 10,000 cells/well were lentivirally transduced 
with IncuCyte® Neurolight Red Lentivirus Reagent for 144 hr. White arrows are highlighting some major 
neuronal processes. 




The cells were plated at a density of 10,000 cells/well, which appeared to be too low 
as it led to cell death. However, it was possible to assess the lentivirus’ ability to pick 
up neurites on the few viable cells. The red channel picked up most of the major and 
minor neuronal processes, similar to what was seen using phase-contrast. It took 
about 2 days after transduction for the red fluorescence to become visible. It should 
be noted however that the red fluorescence was quite weak and was not easily 
detected using the built-in NeuroTrack software. The red channel images in Figure 51 
have had background subtraction and contrast enhancement through ImageJ in order 
to make the neurites more visible for the reader. The lentivirus reagent was not 
noticeably better at picking up neuronal projections than phase-contrast, so phase-



















4.8.2. Cell density optimisation 
To determine the optimal cell density for this assay, a range of cell densities were 
plated and imaged for 72 hours. Three wells were used for each condition. 
 
Figure 52: Neurite retraction cell density optimisation 
Representative IncuCyte® (phase) images of 3 DIV primary mouse hippocampal neurons at densities 
ranging from 10,000 – 60,000 cells/well.  
In the lower cell densities (10,000 and 25,000 cells/well), the cells were very scarce 
and did not have many projections between them. In the higher cell densities 
(40,000 - 60,000 cells/well) the cells began clumping, making it difficult to accurately 
detect neurites with the NeuroTrack software. For these reasons, future experiments 
used a density of 30,000 cells/well, which had an even distribution of cells in the well 











4.8.3. Soluble aggregates cause neurite retraction in primary mouse neurons 
With the imaging protocol and cell density optimised, the assay was carried out using 






Figure 53: Neurite retraction assay 
(a) Representative images of primary mouse hippocampal neurons treated with vehicle control or HPC 
aggregates (from patient AD3) for 80 hr. Vehicle control was aCSF at equal volume to soluble aggregate 
samples. (b) Relative neurite length, normalised to neurite length at the 0-hr time point. Error bars are 
mean ± SD from three wells. (c) The 80-hr time point. Error bars are mean ± SD from three wells.  










































Treatment of primary mouse hippocampal cells with HPC soluble aggregates caused 
significant neurite retraction over 80 hours (Figure 53c). This suggested that the 
soluble aggregates were neurotoxic, similar to what has been previously reported with 
Braak stage VI soluble aggregates.178 However, the glutamate which was added as a 
positive control for neuron-specific degeneration, did not cause significant reduction in 
neurite length. This is most likely due to the cells being treated at 4 DIV (days in vitro), 
which might be too early for maturation and synaptogenesis. Mouse hippocampal 
neurons have been reported to have maximal levels of expressed synaptic markers at 
10 DIV.243 Similarly, rat hippocampal neurons have increased synaptophysin levels 
and mean synaptic firing rate between 7 DIV and 14 DIV.244 Experiments with primary 
mouse hippocampal neurons could not be repeated due to COVID-19 limited access. 
4.8.4. Validation of neurite length assay with a human cell line 
This response was also validated in a human cell line, Lund human mesencephalic 
(LUHMES) cells. These are human embryonic neuronal precursor cells that undergo 
proliferation due to the expression of a tetracycline-regulatable (Tet-off) v-myc 
transgene and can be differentiated into mature dopaminergic neurons with the 
addition of tetracycline.   
4.8.5. Optimisation of neurite length assay with LUHMES neurons  
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Figure 54: Neurite length assay optimisation with LUHMES neurons 
Representative images of the neurite length of LUHMES neurons (6,000 cells/well) treated with 
(a) vehicle control, (b) HPC from AD1, (c) VAC from AD1 or (d) vincristine at 0 and 48-hr time points. 
(e) Relative neurite length of LUHMES neurons at 10,000 cells/well, treated with vehicle, soluble 
aggregates, or vincristine. Normalised to neurite length at the 0-hr time point. Vehicle was aCSF at 
same dilution as soluble aggregate samples, and vincristine (50 nM) served as a positive control for 
neurite retraction. Error bars are mean ± SD from three wells. (f) Statistical analysis of the 48-hr time 
point. Error bars are mean ± SD from three wells. (One-way ANOVA: F(2, 6) = 33.05, p < 0.001. Post 
hoc Tukey test: n = 3 for all: Vehicle vs HPC: p < 0.001; Vehicle vs VAC: p = 0.003; HPC vs VAC: 
p = 0.2). 
This preliminary experiment showed that 48 hours was sufficient for soluble 
aggregate-mediated neurite retraction. Furthermore, the cell density of 10,000 
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4.8.6. Soluble aggregates cause neurite retraction in LUHMES neurons 
The LUHMES neurons were treated with HPC and VAC soluble aggregates from all 















































Figure 55: Soluble aggregates cause neurite retraction in LUHMES neurons 
Representative images of neurite length of LUHMES cells treated with (a) AD1 HPC, (b) AD1 VAC, (c) 
AD2 HPC, (d) AD2 VAC, (e) AD3 HPC, (f) AD3 VAC, (g) vehicle or (h) vincristine, at 0 and 48 hr of 
treatment. (i) Relative neurite length of LUHMES cells (~7,200 cells imaged per condition) treated with 
soluble aggregate samples at a 1:5 dilution for 48 hr, normalised to neurite length at the 0-hr time point 
(1.0), and vincristine at 48 hr (0) to signify total neurite retraction. Vehicle was aCSF at same dilution 
as soluble aggregate samples (1:5), and vincristine (50 nM) served as a positive control for neurite 
retraction. Error bars are mean ± SD from two biological repeats, with each condition carried out in 
triplicate wells, and 4 images analysed per well. (k) Relative neurite length at the 48-hr time point 
averaged by brain region. Each point represents one of three Alzheimer’s disease patients. Error bars 
are mean ± SD. (One-way ANOVA: F(2, 5) = 18.63, p = 0.005. Post hoc Tukey test: n = 3 for all: Vehicle 
vs HPC: p = 0.008; Vehicle vs VAC: p = 0.005; HPC vs VAC: p = 0.84). 
Treatment of LUHMES cells with HPC and VAC soluble aggregates caused significant 
neurite retraction over 48 hours (Figure 55). This suggests that the soluble aggregates 
are neurotoxic, similar to what has been previously reported with Braak stage VI 
soluble aggregates.178  Surprisingly, there was no significant difference between the 
level of HPC and VAC aggregate-induced neurite retraction (Figure 55k). 
To determine whether this neurotoxicity is mediated through the TLR4 receptor, 
LUHMES neurons were pre-incubated with 1 μM TAK242 for 5 hours (as optimised 









4.8.7. Neurite retraction is not mediated through TLR4 
 
Figure 56: Neurite length with TLR4 inhibitor 
Relative neurite length for LUHMES neurons treated with soluble aggregates from patient (a) AD1, (b) 
AD2 and (c) AD3, with and without 5-hr pre-incubation with 1 μM TAK242. (d) Relative neurite length 
for LUHMES neurons treated with LPS and TAK242. Error bars are mean ± SD from three wells.  
Pre-incubation with the TLR4 inhibitor TAK242 did not rescue soluble aggregate-
mediated neurite retraction (Figure 57a-c). This is not surprising, seeing as treatment 
with LPS also did not affect neurite length (Figure 57d). Neurite retraction therefore 
does not appear to be mediated through TLR4, suggesting a different mechanism of 
toxicity. One suggested mechanism is that the Aβ aggregates are acting on the 
mitochondria, leading to caspase 3 activation and neurite retraction.245,246  
The soluble aggregates were then characterised further using the super-resolution 










4.9. Length and number characterisation of soluble aggregates 
AD PAINT imaging and analysis was done by Dr. John Danial and Dr. Jason C. Sang. Figure 57 was created by 
me from their data. 
 
Figure 57: AD PAINT characterisation of soluble aggregates  
(a) Cumulative frequency of soluble aggregates in all eight brain regions and in (b) HPC and VAC 
regions only, from three independent experiments. (Kolmogorov-Smirnov test, AD1: p < 0.001, D = 
0.2092; AD2: p = 0.03, D = 0.0974; AD3: p < 0.001, D = 0.3799; Average: p < 0.001, D = 0.2016). See 
Table 7 for the results of multiple comparison test. (c) Proportion of soluble aggregates over 100 nm in 
length in all eight brain regions and in (d) HPC and VAC regions only. Each point in the AD1, AD2, and 
AD3 graphs represents one of three replicates; each point in the Average graph represents one of three 
Alzheimer’s disease patients. Error bars are mean ± SD. (Unpaired two-tailed t-test, n = 3 for all. AD1: 
p < 0.001, t4 = 16.71; AD2: p = 0.21, t4 = 1.510; AD3: p = 0.002, t4 = 7.618; Average: 





































































































































































































































































































































Table 7: Results from multiple comparisons test for AD PAINT data 
Patient HPC > VAC HPC < VAC Not Significant 
No. of tests 
(#HPC x #VAC) 
AD1 0 9 0 9 (3 x 3) 
AD2 0 3 6 9 (3 x 3) 
AD3 0 9 0 9 (3 x 3) 
Average 0 9 0 9 (3 x 3) 
 
HPC > VAC and HPC < VAC refer to cases where the soluble aggregates in the HPC samples were 
larger or smaller than the VAC aggregates respectively, according to the Kolmogorov-Smirnov test 
(significance level = 0.01). 
The length and number of the soluble aggregates have been characterised by AD 
PAINT super-resolution microscopy. This was performed using an aptamer-docking 
strand that binds to fibrillar Aβ, although it can also bind fibrillary α-synuclein fibrils. 
The complementary imaging strand is then added in buffer and binds transiently to the 
docking strand creating bright spots that can be measured. The aggregates seemed 
to vary from region to region, and from patient to patient. In all cases there was a 
variety of soluble aggregates of a range of lengths detected, however the length 
distributions differed (Figure 57a,c). The HPC aggregates appeared to be shorter than 
VAC aggregates in general, and had a smaller proportion of longer aggregates (over 
100 nm) (Figure 57b,d). Despite the clear difference in length there was a relatively 
small difference between the inflammatory responses of these two regions          
(Figure 38d,e), suggesting that the aggregates smaller than 100 nm (80-95% of all 
aggregates) are most inflammatory.   











4.10. Structural characterisation of aggregates using AFM 
AFM imaging and analysis was done entirely by Dr. Francesco Simone Ruggeri.  
 
Figure 58: High-resolution AFM imaging of aggregates 3-D morphology 
Structural characterisation of the aggregates in (a) HPC and (b) VAC regions using AFM. The blue 
arrows are highlighting toroidal and elongated aggregates. (c) The single aggregate statistical analysis 
of the cross-sectional diameter of the spherical aggregates reveals that VAC spherical aggregates are 
significantly larger than HPC ones (Mann-Whitney test, two-tailed; HPC1 vs VAC1: p < 0.001, 
U = 140761; HPC2 vs VAC2: p < 0.001, U = 56141; HPC3 vs VAC3: p < 0.001, U = 125376). (d) Bar 
plot with SD of the density of the number of elongated protofilaments and toroidal oligomers for μm2 in 
each sample. The graph shows the significant presence of elongated aggregates in the HPC (n1=35, 
n2=17, n3=16 per 20 μm2) compared to the VAC samples (n1=2, n2=0, n3=1 per 20 μm2) (Unpaired 
two-tailed t-test, HPC1 vs VAC1: p = 0.03, t35 = 2.195; HPC3 vs VAC3: p = 0.02, t15 = 2.706). 
(e) Statistical analysis of the cross-sectional length and (f) cross-sectional height of the toroidal, 
prefibrillar and fibrillar aggregates.  
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The 3-D morphology and the heterogeneity of the aggregates from the HPC and VAC 
samples were characterised using high-resolution and phase controlled AFM imaging 
(Figure 58a-b).203,247,248 In both the HPC and the VAC samples, there was an 
abundant presence of spherical aggregates. The single molecule statistical analysis 
of the cross-sectional diameter of these aggregates showed that the spherical 
aggregates present in the HPC samples had a diameter (~30-50 nm) that was 
significantly smaller than the diameter  of the spherical aggregates in the VAC samples 
(~50-80 nm) (Figure 58c). The difference of the average diameter of the aggregates 
is in agreement with the results obtained by AD-PAINT in Figure 57. 
Furthermore, the HPC samples contained several elongated toroidal structures, as 
well as fibrillar and prefibrillar aggregates. The VAC samples contained a significantly 
smaller number of elongated aggregates, and toroidal aggregates were not found in 
the 500 μm2 area of the sample that was imaged in a randomised manner. The 
statistically significant difference in the number of elongated aggregates in the HPC 
vs VAC samples was evaluated by calculating the density of the number of these 
elongated aggregates per μm2 (Figure 58d). The toroidal and fibrillar aggregates had 
an average length of ~100 nm (Figure 58e).  
AFM cannot determine the proteins the toroidal, fibrillar, and spherical structures 
consist of. However, the different heterogeneity of the aggregated species in the HPC 
and VAC samples suggests that there is a regional variability in the structures of 












4.11. Characterisation of Aβ-containing fragments through SiMPull 
SiMPull imaging and analysis was done by Derya Emin, Yu P. Zhang, and Dr Evgenia Lobanova. 
 
Figure 59: SiMPull characterisation of Aβ-containing aggregates 
Cumulative frequency plots of intensity values of Aβ-containing aggregates in HPC and VAC samples 
from (a) AD1 (Kolmogorov-Smirnov test, HPC vs VAC, p < 0.001, D = 0.1987), (b) AD2 (Kolmogorov-
Smirnov test, HPC vs VAC, p < 0.001, D = 0.1451), (c) AD3 (Kolmogorov-Smirnov test, HPC vs VAC, 
p < 0.001, D = 0.0804 ) and (d) Average of the three patients (Kolmogorov-Smirnov test, HPC vs VAC, 
p < 0.001, D = 0.05452). (e) The number of detected spots (Aβ) per field of view (380 x 380 pixel 
cropped images). Each point represents one of three Alzheimer’s disease patients. Error bars are mean 
± SD. (Unpaired two-tailed t-test, HPC vs VAC, n = 3, p = 0.47, t4 = 0.7978). 
Table 8:Results from multiple comparisons test for SiMPull data 
Patient HPC > VAC HPC < VAC Not Significant 
No. of tests 
(#HPC x #VAC) 
AD1 1 1 2 4 (2 x 2) 
AD2 1 2 1 4 (2 x 2) 
AD3 3 1 0 4 (2 x 2) 
Average 2 7 0 9 (3 x 3) 
 
HPC > VAC and HPC < VAC refer to cases where the soluble aggregates in the HPC samples were 
larger or smaller than the VAC aggregates respectively, according to the Kolmogorov-Smirnov test 































































































AD-PAINT and AFM imaging allowed for the characterisation of the morphology, size, 
number, and shape of the soluble aggregates. However, as the techniques are not 
protein-specific, the single-molecule pull-down technique was employed to specifically 
characterise the Aβ-containing aggregates in these samples.249 Intensity values 
provide an approximation of aggregate molecular weight, assuming that more 
fluorescent antibodies bind larger aggregates, and hence an increase in intensity 
correlates with an increase in aggregate size. The intensity values suggested that VAC 
samples contained larger Aβ-containing aggregates than the HPC samples in two out 
of the three patients (Figure 59a-c), and when averaging the three patients         
(Figure 59d). This is in agreement with the AD-PAINT and AFM data, which also 
showed that VAC samples had larger aggregates than HPC samples. There was no 
significant difference in the number of detectable spots per field of view for the two 









4.12. Conclusions and future work 
 
Figure 60: Summary of Chapter 4 major findings 
In this chapter, a method for extracting soluble aggregates by soaking AD brain tissue in buffer has 
been optimised. These soluble aggregates have been found to be inflammatory (most likely driven by 
Aβ-containing aggregates), neurotoxic, liposome-permeable, and have been shown to have regional 
differences in size, morphology and number. 
The only previous study using soluble aggregates extracted from soaking brain tissue 
analysed Braak stage VI AD brains and showed that the major species was Aβ that 
caused LTP deficit and neuronal retraction.178 In this pilot study we wanted to first see 
whether we could detect any aggregates in early disease samples, since this would 
allow us to study earlier events in disease development. We characterised the soluble 
aggregates from eight different brain regions from three Alzheimer’s disease patients 
at Braak stage III. Soluble aggregates from all eight regions were neuroinflammatory 
and liposome-permeable, to varying degrees. This suggests that there is global 
pathology occurring even at Braak stage III. We found extensive variation between the 
same regions in different brains, for example in the aggregate length and number, but 
clear differences between HPC and VAC, since the former is affected very early in 
Alzheimer’s disease and the latter is largely unaffected until late disease. We therefore 




chose to compare the soluble aggregates in HPC and VAC regions using all assays, 
with VAC serving as an internal control for each patient.  
Despite patient-to-patient variability, HPC aggregates appeared to be the most toxic 
(Figure 38,38). TNFα secretion in response to soluble Aβ aggregates has been 
previously reported to cause long-term potentiation deficit,218 a cellular correlate of 
memory loss, so together with our data showing inflammation being highest in the 
hippocampus, this offers an explanation as to why memory loss occurs in AD. 
Neurite retraction induced by soluble aggregates occurred within 24-48 hours    
(Figure 55i), whereas the microglial TNFα response to the same concentration of 
soluble aggregates arose after 72-96 hours (Figure 38a-d). This might suggest that 
neurons are more sensitive to soluble aggregates than microglia, although this could 
simply be a result of different cell densities used for the experiments. Furthermore, this 
might not be the case in the actual disease condition where neurons are in constant 
crosstalk with glial cells, which may have neuroprotective or neurotoxic properties. It 
would be interesting in future experiments to try adding the supernatant from microglia 
treated with soluble aggregates, which should be full of proinflammatory cytokines and 
chemokines, to neurons, and in that way measure the direct effect of aggregate-
induced neuroinflammation on neurotoxicity, as has been done previously.250–252 It 
would also be interesting to grow a co-culture of neurons and glial cells and treat them 
with soluble aggregates. The use of AD patient-derived iPSCs would also increase the 
clinical relevance of these experiments. 
We have identified the size, length, morphology and number of these endogenous 
soluble aggregates. These varied from region to region and from patient to patient but 
importantly there was a range of aggregates of different sizes (20-200 nm) in all 
regions. It should be noted that the aptamer used for the AD-PAINT studies can bind 
both Aβ and α-synuclein, however our work167,186 and previous work178 suggests that 
it is most likely Aβ. Furthermore, AFM imaging is not protein specific, but the sizes of 
the imaged aggregates are consistent with those measured with AD-PAINT, similar to 
what was observed in our previous work on CSF.186 
We have taken advantage of the high-resolution of AFM to further characterise the 
morphology and structure of soluble aggregates from the hippocampus and the visual 
association cortex. HPC samples contained structures of toroidal nature, as well as 




fibrillar structures. VAC samples rarely had fibrillar structures and contained many 
spherical structures. We have found in CSF186 and with synthetic aggregates167 that 
protofibrils are the main inflammatory species. This is likely because they are the right 
diameter to be bound by multiple toll-like receptor 4s (TLR4s). Indeed, in the HPC 
samples about 7-15% of the aggregates detected by AFM have the right height 
(~2 nm) to produce a strong inflammatory response, compared to the proportion in the 
VAC, which is less than 2%. These aggregates were less than 100 nm in length, which 
is also consistent with our observation, combining our AD-PAINT and inflammatory 
assay results, that the inflammatory aggregates are less than 100 nm in length. 
Overall, our data suggests that fibrillary aggregates less than 100 nm in length and 
2 nm in diameter can cause inflammation and that there are more of these aggregates 
in the HPC compared to the VAC.  
A previous study has found that activated microglia are present in HPC and VAC in 
Alzheimer’s disease patients classed as having low neuropathologic change.53 Both 
the HPC and VAC already had some activated microglia. It was found that there are 
more microglia and more activated microglia in HPC than VAC, but an increase in the 
proportion of activated microglia occurred in both areas at early stages. This is 
supported by cross-sectional studies, which have used PET scans to detect activated 
microglia, and have shown increases in inflammation in early disease all over the brain 
that is associated with cognitive decline.253–255 Peripheral cytokine studies have shown 
that this increase in inflammation in early disease plateaus in later stages of the 
disease.256–259 In combination with our work, this suggests that instead of aggregates 
spreading through the brain, the same aggregate-induced inflammation is occurring 
locally to a greater or lesser extent in the entire brain simultaneously. 
In AD, Aβ has been reported to spread from neocortical areas to the brainstem and 
cerebellum, and tau spreading from the temporal lobe, which includes the entorhinal 
cortex and hippocampus, to limbic and association areas.16,260 Several mechanisms 
for this spreading have been proposed, including the “transneuronal spread model” 
where toxic aggregates spread along neuronal connections in a prion-like manner,261 
and local spreading where aggregates spread to physically adjacent regions, via 
release into the extracellular space and then taken up by nearby neurons or glial 
cells.262–264 Another possibility is that the toxic proteins are not spreading themselves; 
instead neuroinflammation is spreading from region to region, inducing the 




aggregation of toxic proteins in each region, as supported by the presence of 
neuroinflammatory soluble aggregates in all eight regions (Figure 38). Microglial 
activation has been reported to correlate with the spread of tau pathology, further 
supported by reports suggesting microglia might induce tau hyperphosphorylation as 
well as take-up and release of tau seeds that couldn’t be broken down, into the 
extracellular space.265,266 This suggests that microglia might play an important role in 
the spread of tau pathology, however this might not be the case for soluble Aβ. Recent 
studies have shown that microglia do not appear to take up and transport soluble Aβ, 
but instead degrade them by secreting insulin-degrading enzyme (IDE).267 If the 
spread of toxic proteins is mediated partly by neuroinflammation, the challenge 
remains to understand why neuroinflammation spreads differently in different 
neurodegenerative diseases, such as AD and Parkinson’s disease. It is possible that 
the extent of inflammation and where it starts might determine how different 
neurodegenerative diseases form and spread. For example, traumatic brain injury is 
a major insult with high inflammation and rapid spreading, while AD may have low 
long-term levels of inflammation that spread more slowly. To get a stronger 
understanding of the mechanisms of spreading and the differences between 
neurodegenerative diseases, future work could look into other toxic aggregates, such 
as tau, α-synuclein, and TDP-43, as well as brain tissue from patients with other 
neurodegenerative disorders. Spreading most likely occurs from a combination of 
mechanisms occurring simultaneously, with neuroinflammation and toxic proteins 
spreading together and inducing each other in a positive feed-back loop manner.  
It should be noted that our study was intended to determine the feasibility of this 
approach and has been performed on a small number of Alzheimer’s disease patients 
due to the manual nature of these experiments. The Klenerman group is currently 
working on automating these assays to allow for more high-throughput assessment of 
Alzheimer’s disease brain tissue, to explore whether similar characteristics of soluble 
aggregates are found in larger cohorts and allow comparison to age matched control 
brain and brain at later stages of AD. More sensitive neuroinflammation assays are 
also needed to better characterise the inflammatory properties of aggregates from 
different brain regions. Examples of this include the TNFα imaging experiments 
described in Chapter 3, complemented with either flow cytometry or Incucyte live-cell 
imaging, which could be optimised for brain-derived soluble aggregates. A 




combination of automated high-throughput and highly sensitive assays would have the 
potential to characterise the aggregates that form in humans during the development 
of AD and identify which aggregates are toxic and by what mechanisms. By studying 
regions where inflammatory aggregates are just starting to be formed, it may be 
possible to study the early processes of disease. In the future, AD brains from other 
Braak stages should be analysed, to gain a stronger understanding of the relationship 
between soluble Aβ aggregates and disease progression. 
Overall, our data is consistent with small soluble Aβ-containing aggregates, 2 nm in 
diameter and less than 100 nm in length, driving inflammation in Alzheimer’s disease 
to greater or lesser extents in all regions of the brain and this aggregate-induced 
inflammation then causing cellular dysfunction and ultimately cell death. Our study 
also highlights the heterogeneity in size, morphology and structure of the aggregates 
formed in the brain with the proportion of different aggregates differing between brain 
regions. It also highlights the challenges in selectively targeting the correct species 
and suggests that targeting the aggregate induced inflammation may be a better 
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